• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to the control of skin conditions comprising topical application of a composition containing a vitamin B 3 compound, in particular niacinamide. The invention also relates to the control of skin conditions comprising topical application of a composition containing a vitamin B 3 compound, in particular niacinamide, and a retinoid. The present invention provides for the control of the visible and / or tactile discontinuity of mammalian skin tissues, including the topical application of the composition, in particular controlling the signs of skin aging, more specifically discontinuities associated with aged skin. It's about doing. The present invention relates to the prophylactic and therapeutic control of skin conditions. In a preferred embodiment, the vitamin B 3 compound is not substantially in salt form, is uncomplexed, the vitamin B 3 compound is niacinamide, and the carrier contains a hydrophilic diluent.
    公开号:KR20000010622A
    申请号:KR1019980708523
    申请日:1997-04-23
    公开日:2000-02-25
    发明作者:존 에리치 오블롱；도날드 린 비셋트；킴벌리 앤 비더만
    申请人:데이비드 엠 모이어；더 프록터 앤드 갬블 캄파니；
    IPC主号:
    专利说明:

    How to control skin appearance with vitamin B3 compounds
    This application is filed under U.S. Provisional Application No. 60 / 016,043, filed April 23, 1996, and U.S. Provisional Application Nos. 60 / 025,242, filed Sep. 16, 1996, and 10, 1996, under U.S. Patent Act 119 (e). Claims priority of US Provisional Application No. 60 / 028,902, filed May 21. This application is a partially-continued application of US patent application Ser. No. 08 / 554,067, filed November 6, 1995.
    Many personal care products currently available to consumers are primarily for improving the health and / or physical appearance of the skin. Among these skin care products, many are intended to delay, minimize or even eliminate skin wrinkles and other histological changes in human skin, typically associated with aging of the skin or environmental damage.
    The skin is damaged by many external and internal factors. External factors include ultraviolet (eg, due to sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like. Internal factors include natural aging and other intradermal biochemical changes. These factors, whether external or internal, can cause skin aging and environmental damage, such as wrinkles and other types of roughness (including increased pore size, flaking, skin lines, etc.), and those associated with skin aging or damage. Visible signs of external histological changes appear. For many people, skin wrinkles make us think of the disappearance of youth. As a result, wrinkle removal has become a promising business in youth-oriented societies. Treatments range from cosmetic creams and moisturizers to various cosmetic surgical procedures.
    External or internal factors can cause skin thinning and general degeneration. For example, as the skin ages naturally, the number of cells decreases and the number of blood vessels supplied to the skin decreases. In addition, the skin-epidermal connection is flattened, which weakens the mechanical resistance of the skin-epidermal connection. See, for example, Oikarinen, "The Aging of Skin: Chronoaging Versus Photoaging", Photodermatol. Photoimmunol. Photomed., Vol. 7, pp. 3-4, 1990.
    It has now been found that vitamin B 3 compounds, including niacinamide, provide an advantage in controlling skin conditions known to the inventors and not known in the art. For example, topical niacinamide regulates the signs of skin aging. For example, it reduces or eliminates fine lines, wrinkles and other uneven or rough surface tissues associated with aged or photodamaged skin. In addition, topical compositions containing vitamin B 3 compounds and retinoids have been found to be beneficial in controlling skin conditions known to the inventors and not known in the art. For example, such compositions can modulate signs of skin aging while reducing the likelihood of retinoid dermatitis. In addition, the combination of vitamin B 3 compounds with certain retinoids synergistically regulates the signs of skin aging, particularly the visible and / or tactile discontinuity of skin tissue associated with aged skin, including fine lines and wrinkles.
    Accordingly, it is an object of the present invention to contain vitamin B 3 compounds, in particular niacinamide, for prophylactically / prophylactically or therapeutically regulating the skin condition of mammals (especially human skin, more particularly facial skin). It is to provide a topical composition.
    Another object of the present invention is to provide a topical composition containing a vitamin B 3 compound, in particular niacinamide, for prophylactically / prophylactically or therapeutically controlling the signs of skin aging in a mammal.
    Another object of the present invention is to prevent and / or prevent visible and / or tactile discontinuity of mammalian skin tissue, including fine lines, wrinkles, enlargement of pores, roughness, and other skin tissue discontinuities associated with aged skin. It is to provide a topical composition containing a vitamin B 3 compound, in particular niacinamide, for therapeutic control.
    Another object of the present invention is to provide the topical composition further comprising a retinoid.
    The invention also relates to a method of providing such control using the composition.
    These and other objects of the present invention will become apparent from the following disclosure.
    Summary of the Invention
    The present invention relates to the control of skin conditions comprising topical application of a composition containing a vitamin B 3 compound, in particular niacinamide. The invention also relates to the control of skin conditions comprising topical application of a composition containing a vitamin B 3 compound, in particular niacinamide, and a retinoid. In particular, the present invention provides for the control of signs of skin aging, including topical application of the composition, and more specifically for the visible and / or tactile discontinuity of skin tissue in mammals, including discontinuities associated with aged skin. It's about adjusting. The present invention relates to the prophylactic and therapeutic control of skin conditions.
    In a preferred embodiment, the vitamin B 3 compound is not substantially in salt form, is uncomplexed, the vitamin B 3 compound is niacinamide, and the carrier contains a hydrophilic diluent.
    The present invention relates to topical compositions containing vitamin B 3 compounds for regulating skin conditions, in particular for controlling the visible and / or tactile discontinuity of the skin in connection with skin aging and the like. Preferred compositions contain niacinamide.
    All percentages and ratios used herein are based on the weight of the entire composition, unless otherwise indicated, and all measurements are made at 25 ° C.
    The compositions of the present invention comprise, consist essentially of, or consist of optional ingredients as well as ingredients described herein. As used herein, “consisting essentially of” means that the composition or components may comprise additional components, provided that the additional components do not substantially change the basic and novel characteristics of the claimed composition or method. .
    All publications cited herein are hereby incorporated by reference in their entirety.
    As used herein, the term "topical application" means the application or application of a composition of the invention to the skin surface.
    As used herein, the term "dermatologically acceptable" means that the composition or component so described is suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic reactions, and the like.
    As used herein, the term “a safe and effective amount” is sufficient to provide a benefit (preferably independently a positive skin appearance or feel benefit including the benefits disclosed herein) and to avoid serious side effects. By low the amount of a compound or composition within the scope of sound judgment by one of ordinary skill in the art (ie, to the extent that it provides a reasonable advantage in risk ratio).
    The compositions of the present invention are useful for topical application and for controlling skin conditions, including visible and / or tactile discontinuities (particularly skin surfaces; such discontinuities are generally undesirable). Such discontinuities may be induced or caused by internal and / or external factors and include the signs of skin aging described herein. "Control of skin condition" includes prophylactically and / or therapeutically controlling skin conditions, including the visible and / or tactile discontinuity of the skin. As used herein, prophylactically controlling the skin condition includes delaying, minimizing and / or preventing the visible and / or tactile discontinuity of the skin. As used herein, therapeutically controlling the skin condition includes improving (eg, reducing, minimizing and / or eliminating) discontinuity of the skin. Modulation of the skin condition includes improving skin appearance and / or feel.
    The compositions of the present invention are useful for controlling the signs of skin aging, more specifically the visible and / or tactile discontinuity of skin tissue associated with aging. "Controlling signs of skin aging" prophylactically and / or therapeutically control one or more signs (similarly, controlling signs of skin aging, such as lines, wrinkles or pores, are signs Prophylactically and / or therapeutically. As used herein, prophylactically controlling such signs includes delaying, minimizing and / or preventing skin aging. As used herein, therapeutically controlling such signs includes improving (eg, reducing, minimizing and / or eliminating) signs of skin aging.
    "Signs of skin aging" include, but are not limited to, all the perceptible indications that can be seen and felt and any other huge or smile effects due to skin aging. Such indications may be induced or caused by damage by internal or external factors such as natural aging and / or the environment. These signs include wrinkles (eg, fine epidermal wrinkles and rough deep wrinkles), skin glands, ruptures, bumps, large pores (eg, holes associated with appendage structures such as sweat glands, sebaceous glands or hair follicles), peeling, flaking and And / or other uneven or rough skin form, loss of skin elasticity (loss and / or inactivation of functional skin elasticity), sag (eg, swelling under the eyes and chin), loss of skin firmness, loss of skin tightening Loss of skin rebound from deformation, discoloration (e.g. circles under the eyes), swelling, hyperpigmentation, hyperpigmented skin areas (e.g. blotch and freckles), keratin, abnormal differentiation, hyperkeratosis, elastic fibrosis, collagen breakdown And development of tissue discontinuities such as corneal layer, skin, epidermis, cutaneous vascular system (e.g. capillary telangiectasia or arachnoidoma) and other histological changes in tissues below it, particularly in close proximity to the skin. That also (without limitation) can occur as a result of the process.
    The present invention is not limited to the above-mentioned control of "signs of skin aging" caused by mechanisms related to skin aging, and of course includes control of signs independent of the causative mechanism. As used herein, "modulation of the skin condition" includes the control of indications independent of the causative mechanism.
    It is particularly useful for therapeutically controlling the visible and / or tactile discontinuities of skin tissue of mammals, including discontinuities of tissues associated with skin aging of the present invention. As used herein, therapeutically controlling such discontinuities also includes an improvement in, for example, reduction, minimization and / or removal of visible and / or tactile discontinuities of the skin tissue of a mammal, thereby improving skin appearance. And / or provide a feel (eg, make the skin appearance and / or feel smoother and more uniform). Visible and / or tactile discontinuities of such skin tissues include ruptured, nodules, pores, fine lines, wrinkles, flaking, flaking and / or other tissue irregularities or roughness associated with skin aging. For example, the length, depth and / or other dimensions of the lines and / or wrinkles are reduced, the apparent diameter of the pores is reduced, or the apparent height of the tissue immediately adjacent to the pores is close to the height of the skin of the appendage.
    The present invention is also particularly useful for prophylactically controlling the visible and / or tactile discontinuities of mammalian tissues, including those associated with skin aging. As used herein, prophylactically controlling such discontinuities includes delaying, minimizing and / or preventing visible and / or tactile discontinuities of mammalian skin tissue, thus providing improved skin appearance and / or feel. (E.g., to make the skin appearance and / or feel smoother and more uniform).
    The composition of the present invention is useful for promoting exfoliation of the skin. Without being bound by theory, it is believed that compositions containing vitamin B 3 compounds, especially niacinamide, enhance the energy state of the skin that controls exfoliation to normalize epidermal differentiation and keratinization.
    Vitamin B 3 Ingredients
    The composition of the present invention comprises a safe effective amount of a vitamin B 3 compound. The composition of the present invention is preferably from about 0.01% to about 50%, more preferably from about 0.1% to about 10%, even more preferably from about 0.5% to about 10%, even more preferably from about 1% to About 5%, most preferably about 2% to about 5% of a vitamin B 3 compound.
    As used herein, a "vitamin B 3 compound" is a compound having the formula:

    Wherein R is -CONH 2 (ie niacinamide), -COOH (ie nicotinic acid) or -CH 2 OH (ie nicotinyl alcohol), derivatives thereof, and salts thereof.
    Examples of the derivatives of the aforementioned vitamin B 3 compounds are nicotinic acid esters (eg, non-vascular expandable esters of nicotinic acid), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxides and niacinamide N-oxides.
    Suitable esters of nicotinic acid include nicotinic acid esters of C 1 -C 22 , preferably C 1 -C 16 , more preferably C 1 -C 6 alcohols. Alcohols are suitably in straight or branched chain, cyclic or bicyclic, saturated or unsaturated (including aromatic) and substituted or unsubstituted forms. The ester is preferably nonvascular dilatable. As used herein, "nonvascular vasodilation" means that the ester generally does not cause a strong visible reaction after application to the skin in the form of the composition (this compound causes vasodilation not visible to the naked eye). But most common populations will not experience strong visible reactions). Non-vascular expanding esters of nicotinic acid include tocopherol nicotinate and inositol hexanicotinate, with tocopherol nicotinate being preferred.
    Other derivatives of vitamin B 3 compounds are derivatives of niacinamide resulting from the substitution of one or more amide group hydrogens. Non-limiting examples of niacinamide derivatives useful herein include, for example, nicotinyl amino acids and organic carboxylic acids (eg, C 1 −) derived from the reaction of an activated nicotinic acid compound (eg, nicotinic acid azide or nicotinyl chloride) with an amino acid. C 18 ) nicotinyl alcohol ester. Specific examples of such derivatives are nicotinuric acid (C 8 H 8 N 2 O 3 ) and nicotinyl hydroxamic acid (C 6 H 6 N 2 O 2 ) having the following chemical structures:
    Nicotinuric acid

    Nicoyl Hydroxamic Acid

    Examples of nicotinyl alcohol esters include nicotinyl alcohol esters such as carboxylic acid, salicylic acid, acetic acid, glycolic acid, palmitic acid and the like. Other non-limiting examples of vitamin B 3 compounds useful herein include 2-chloronicotinamide, 6-aminonitotinamide, 6-methylnicotinamide, n-methylnicotinamide, n, n-diethylnicotinamide, n- (Hydroxymethyl) -nicotinamide, quinoline acid imide, nicotinanilide, n-benzyl nicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isnicotinic acid, methyl isniconicotinic acid, thioninicotinamide, nial Mead, 1- (3-pyridylmethyl) urea, 2-mercaptonicotinic acid, nicomol and niaprazine.
    Examples of such vitamin B 3 compounds are well known in the art and include Sigma Chemical Company, St. Louis, Missouri; ICN Biomedicals, Inc. (ICN Biomedicals, Inc., Irvine, CA) and Aldrich Chemical Compnay (Milwaukee, WI) can be purchased from a number of sources.
    One or more vitamin B 3 compounds can be used herein. Preferred vitamin B 3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is more preferred.
    When used, salts, derivatives and salt derivatives of niacinamide are preferably those which exhibit substantially the same efficacy as niacinamide in the methods of modulating the skin conditions described herein.
    Salts of vitamin B 3 compounds are also useful herein. Non-limiting examples of vitamin B 3 compounds include inorganic salts with anionic inorganic species such as chlorides, bromides, iodides, carbonates, preferably chlorides, and organic carboxylic acid salts such as acetates, salicylates, Organic or inorganic salts such as mono-, di- and tri-C 1 -C 18 carboxylic acid salts, preferably monocarboxylic acid salts such as acetates) such as glycolate, lactate, maleate, citrate and the like. These and other salts of vitamin B 3 compounds are described, for example, in W. Wenner, "The Reaction of L-Ascorbic and D-Isosascorbic Acid with Nicotinic Acid and Its Amide", J. Organic Chemistry, Vol. 14, 22-26 (1949), which can be readily prepared by one skilled in the art.
    In a preferred embodiment, the cyclic nitrogen of the vitamin B 3 compound is substantially chemically free (eg, unbound and / or impaired) or substantially chemically free after delivery to the skin ("chemically Free "is also referred to as" unattached "later). More preferably, the vitamin B 3 compound is essentially uncomplexed. Thus, if the composition contains a vitamin B 3 compound in salt or otherwise complexed form, the complex is preferably substantially reversible and more preferably essentially reversible when the composition is delivered to the skin. For example, such complexes should be substantially reversible at pH of about 5.0 to about 6.0. Such reversibility can be readily determined by one skilled in the art.
    More preferably, the vitamin B 3 compound is substantially uncomplexed in the composition prior to delivery to the skin. Examples of methods for minimizing or preventing the formation of undesirable complexes include the exclusion of substances that form complexes or other complexes that are substantially irreversible with vitamin B 3 compounds, pH adjustment, ionic strength control, the use of surfactants and vitamins There is a combination of the B 3 compound and the substance complexed with it in different phases. Such a method is possible at the level of those skilled in the art.
    Thus, in a preferred embodiment, the vitamin B 3 compound contains a limited amount of salt form, more preferably substantially no salt of the vitamin B 3 compound. Preferably, the vitamin B 3 compound contains less than about 50% of such salts, more preferably essentially free of salt form. Vitamin B 3 compounds in compositions having a pH of about 4 to about 7 typically contain less than about 50% salt form.
    Vitamin B 3 compounds may be included as substantially pure substances or as extracts obtained by suitable physical and / or chemical isolation from natural sources (eg, plants). The vitamin B 3 compound is preferably substantially pure, more preferably essentially pure.
    carrier
    The composition of the present invention comprises a dermatologically acceptable carrier incorporating a vitamin B 3 compound so as to deliver the vitamin B 3 compound and optionally other active substances to the skin at a suitable concentration. Thus, the carrier can act as a diluent, dispersant, solvent, and the like to be applied and evenly distributed to a selected target at a suitable concentration.
    The carrier may contain one or more dermatologically acceptable solid, semisolid or liquid fillers, diluents, solvents, extenders and the like. The carrier may be a solid, semisolid or liquid. The carrier itself may be inert or have dermatological benefits on its own. The concentration of the carrier may vary depending on the carrier selected and the planned concentrations of the essential and optional ingredients.
    Suitable carriers include conventional or known carriers which are dermatologically acceptable. The carrier must also be physically and chemically compatible with the essential ingredients described herein and must not unduly detract from the stability, efficacy or other use advantages associated with the compositions of the present invention. Preferred components of the compositions of the present invention should be capable of mixing under normal use circumstances such that there is no interaction that substantially degrades the efficacy of the composition.
    The type of carrier used in the present invention depends on the type of product form desired for the composition. Topical compositions useful in the present invention can be prepared from a variety of products such as those known in the art. Non-limiting examples of these include solids, semisolids, including lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics (e.g. foundations, eye cosmetics, pigmented or non-pigmented lip treatments such as lipsticks) Liquid cosmetics). These product forms may include several types of carriers, including but not limited to solutions, aerosols, emulsions, gels, solids and liposomes.
    Preferred carriers contain a dermatologically acceptable hydrophilic diluent. As used herein, "diluent" includes substances into which the vitamin B 3 compound may be dispersed, dissolved or otherwise incorporated. Hydrophilic diluents include water, organic hydrophilic diluents [e.g. lower monohydric alcohols (e.g. C 1 -C 4 ) and low molecular weight glycols and polyols (e.g. propylene glycol, polyethylene glycols (e.g. 600 g), polypropylene glycol (e.g., 425-2025 g per mole), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol ester, 1,2,6-hexanetriol, ethanol, isopropanol, Sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers and mixtures thereof). Water is the preferred diluent. The composition preferably comprises about 80% to about 99.99% hydrophilic diluent and the aforementioned amount of the vitamin B 3 compound.
    The solution according to the invention typically comprises a dermatologically acceptable hydrophilic diluent. Solutions useful in the present invention preferably contain from about 80% to about 99.99% hydrophilic diluent and the aforementioned amounts of vitamin B 3 compounds.
    The aerosol according to the invention can be formed by adding propellant to the solution as described above. Examples of propellants are chloro-fluorinated low molecular weight hydrocarbons. Still other propellants useful herein are described in Sagarin, Cosmetics Science and Technology, 2nd ed., Vol. 2, pp. 443-465 (1972). Aerosols are typically used as a spray-on product on the skin.
    Preferred carriers include emulsions such as oil-in-water emulsions, water-in-oil emulsions and water-in-silicone emulsions. As will be appreciated by those skilled in the art, depending on the water solubility / water dispersibility of the components in the composition, a given component will mainly be distributed in water or oil / silicone phase. Preferred vitamin B 3 compounds are mainly distributed in the aqueous phase. Oil-in-water emulsions are particularly preferred.
    Emulsions according to the invention generally contain solutions and fats and oils as described above. Oils and fats can be derived from animals, plants or petroleum and can be natural or synthetic (ie artificially). Preferred emulsions also contain humectants, such as glycerin. The emulsion will preferably further contain from about 1% to about 10%, more preferably from about 2% to about 5%, based on the weight of the carrier. Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are described, for example, in US Pat. No. 3,755,560 to Dickert, et al., August 28, 1973; US Patent No. 4,421,769 to Dixon et al. On December 20, 1983; And McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986).
    The emulsion may also contain an antifoam to minimize foaming when applied to the skin. Antifoaming agents include high molecular weight silicones and other materials known in the art for such uses.
    Suitable emulsions may have a wide range of viscosities, depending on the desired product form. Preferred typical low viscosity emulsions have a viscosity of about 50 centistokes or less, more preferably about 10 centistokes or less and most preferably about 5 centistokes or less.
    Preferred water-in-silicone emulsions and oil-in-water emulsions are described in more detail below.
    a) water-in-silicone emulsion
    The water-in-silicone emulsion contains a continuous silicone phase and a dispersed aqueous phase.
    (i) continuous silicon phase
    Preferred water-in-silicone emulsions of the present invention comprise from about 1% to about 60%, preferably from about 5% to about 40%, more preferably from about 10% to about 20% by weight of the continuous silicone phase. . The continuous silicon phase is present as an external phase containing or surrounding the discrete water phase described later.
    The continuous silicone phase contains polyorganosiloxane oils. Preferred water-in-silicone emulsion systems are formulated to provide an oxidatively stable vehicle for optional retinoids. The continuous silicone phase of this preferred emulsion comprises from about 50% to about 99.9% by weight of organopolysiloxane oil and less than about 50% by weight of non-silicone oil. In a particularly preferred embodiment the continuous silicone phase is at least about 50%, preferably from about 60% to about 99.9%, more preferably from about 70% to about 99.9%, even more preferably about 80% by weight of the continuous silicon phase. To about 99.9% polyorganosiloxane oil, and up to about 50%, preferably less than about 40%, more preferably less than about 30%, even more preferably less than about 10% by weight of the continuous silicone phase, Most preferably less than about 2% non-silicone oil. This preferred emulsion system provides long term superior oxidative stability to retinoids than equivalent water-in-oil emulsions containing lower concentrations of polyorganosiloxane oils. The concentration of non-silicone oil in the continuous silicone phase is minimized or absent to further enhance the oxidative stability of the selected retinoids in the composition. This type of silicone water emulsion is, in the name of Joseph Michael Zukowski, Brent William Mason, Larry Richard Robinson and Greg George Hillebrand, which is incorporated herein by reference. Described in co-pending US patent application Ser. No. 08 / 570,275, filed December 11, 1995.
    Organopolysiloxane oils for use in the composition may be volatile, nonvolatile or a mixture of volatile and nonvolatile silicones. As used herein, the term "nonvolatile" refers to silicone having a liquid at ambient conditions and a flash point (at one atmospheric pressure) of about 100 ° C. or higher. The term "volatile" as used herein refers to all other silicone oils. Suitable organopolysiloxanes can be selected from a variety of silicones having a wide range of volatility and viscosities. Examples of suitable organopolysiloxane oils are polyalkylsiloxanes, cyclic polyalkylsiloxanes and polyalkylarylsiloxanes.
    Polyalkylsiloxanes useful in the compositions herein include polyalkylsiloxanes having a viscosity at about 25 ° C. of from about 0.5 to about 1,000,000 centistokes. Such polyalkylsiloxanes may be represented by the general formula R 3 SiO [R 2 SiO] x SiR 3 , wherein R is an alkyl group having 1 to about 30 carbon atoms (preferably R is methyl or ethyl, more preferably Is methyl and mixed alkyl groups may be used in the same molecule); x is an integer from 0 to about 10,000 selected to obtain a desired molecular weight that may exceed about 10,000,000. Commercially available polyalkylsiloxanes include polydimethylsiloxane, also known as dimethicone, examples of which are the Vicasil series and Dow Corning sold by General Electric Company. Dow Corning® 200 series, available from Dow Corning Corporation. Specific examples of suitable polydimethylsiloxanes include, but are not limited to, Dow Corning 200 fluid having a viscosity of 0.65 centistokes and a boiling point of 100 ° C; Dow Corning 225 fluid having a viscosity of 10 centistokes and a boiling point above 200 ° C .; And Dow Corning 200 fluid having a viscosity of 50,350 centistokes and 12,500 centistokes and a boiling point higher than 200 ° C. Suitable dimethicones are those represented by the general formula (CH 3 ) 3 SiO [(CH 3 ) 2 SiO] x- [CH 3 RSiO] y Si (CH 3 ) 3 (wherein R is from 2 to about 30 carbon atoms). Is a straight or branched chain alkyl of and x and y are each an integer of 1 or more selected to obtain a desired molecular weight that may be greater than about 10,000,000 each). Examples of these alkyl-substituted dimethicones are cetyl dimethicone and lauryl dimethicone.
    Suitable cyclic polyalkylsiloxanes for use in the present compositions are those represented by the general formula [SiR 2 -O] n , wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably Is methyl), n is an integer from about 3 to about 8, more preferably an integer from about 3 to about 7, most preferably an integer from about 4 to about 6. Wherein R is methyl, these materials are typically called cyclomethicone. Commercially available cyclomethicones include Dow Corning 244 fluid having a viscosity of 2.5 centistokes, a boiling point of 172 ° C., and predominantly containing cyclomethicone tetramers (ie, n = 4); Dow Corning 344 fluid having a viscosity of 2.5 centistokes and a boiling point of 178 ° C. and containing mainly cyclomethicone pentameric (ie, n = 5); Dow Corning 245 fluid having a viscosity of 4.2 centistokes and a boiling point of 205 ° C. and containing mainly cyclomethicone tetramers and pentamers (ie, n = 4 and 5); And a Dow Corning 345 fluid having a viscosity of 4.5 centistokes and a boiling point of 217 ° C. and containing primarily a mixture of cyclomethicone tetramers, pentamers and hexamers (ie n = 4, 5 and 6).
    Also useful are materials such as trimethylsiloxysilicate, a polymeric material corresponding to the general formula [(CH 2 ) 3 SiO 1/2 ] x [SiO 2 ] y (where x is an integer from about 1 to about 500, and y Is an integer from about 1 to about 500). Commercially available trimethylsiloxysilicate is commercially available as a Dow Corning 593 fluid as a mixture with dimethicone.
    Dimethiconols are also useful for use in the present compositions. This compound may be represented by the formula: R 3 SiO [R 2 SiO] x SiR 2 OH and HOR 2 SiO [R 2 SiO] x SiR 2 OH, wherein R is an alkyl group (preferably R is methyl or Ethyl, more preferably methyl), x is an integer from 0 to about 500 selected to obtain the desired molecular weight. Commercially available dimethiconols are typically commercially available as a mixture with dimethicone or cyclomethicone (eg, Dow Corning 1401, 1402 and 1403 fluids).
    Polyalkylaryl siloxanes are also suitable for use in the present compositions. Particularly useful are polymethylphenyl siloxanes having a viscosity at 25 ° C. of about 15 to about 65 centistokes.
    Organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethicones, polyalkylaryl siloxanes and mixtures thereof are preferred for use herein. Polyalkylsiloxanes and cyclomethicones are more preferred for use herein. Of the polyalkylsiloxanes, dimethicone is preferred.
    As mentioned above, the continuous silicone phase may contain one or more non-silicone oils. The concentration of non-silicone oil in the continuous silicone phase is preferably minimized or absent to further enhance the oxidative stability of the selected retinoids in the composition. Melting points of suitable non-silicone oils are about 25 ° C. or less at about 1 atmosphere. Examples of non-silicone oils suitable for use on continuous silicone phases are well known in the chemical art of topical body care products in the form of water-in-oil emulsions such as mineral oils, vegetable oils, synthetic oils, semi-synthetic oils and the like.
    (ii) distributed water
    The topical composition of the present invention comprises from about 30% to about 90%, more preferably from about 50% to about 85%, most preferably from about 70% to about 80% of the dispersed aqueous phase. In emulsion techniques, the term "dispersed phase" is a term well known to those skilled in the art, meaning that the phase is present as small particles or droplets suspended and surrounded by the continuous phase. The dispersed phase is also known as the internal phase or discontinuous phase. The dispersed aqueous phase is a dispersion of small aqueous particles or droplets suspended and surrounded by the aforementioned continuous silicone phase.
    The water phase may be water or may be a mixture of water and one or more water soluble or water dispersible ingredients. Non-limiting examples of such optional ingredients include thickeners, acids, bases, salts, chelating agents, gums, water soluble or water dispersible alcohols and polyols, buffers, preservatives, sunscreens, colorants and the like.
    Topical compositions of the present invention typically contain from about 25% to about 90%, preferably from about 40% to about 80%, more preferably from about 60% to about 80, of water in the aqueous phase dispersed by weight of the composition Included in%.
    (iii) emulsifiers to disperse the aqueous phase
    The water-in-silicone emulsion of the present invention preferably contains an emulsifier. In a preferred embodiment, the composition contains from about 0.1% to about 10%, more preferably from about 0.5% to about 7.5%, most preferably from about 1% to about 5% of an emulsifier, based on the weight of the composition. Emulsifiers allow the aqueous phase to be dispersed and suspended in a continuous silicone phase.
    Various emulsifiers can be used herein to form the desired water-in-silicone emulsions. If the selected emulsifier is chemically and physically compatible with the essential components of the composition, known or conventional emulsifiers can be used in the composition, which provide the desired dispersion characteristics. Suitable emulsifiers include silicone emulsifiers, silicone-free emulsifiers and mixtures thereof known to those skilled in the art for use in topical body care products. Preferably, the hydrophilic lipophilic equilibrium (HLB) value of these emulsifiers is about 14 or less, more preferably about 2 to about 14, most preferably about 4 to about 14. Emulsifiers having an HLB value outside this range may be used in combination with other emulsifiers so that the effective weight average HLB of the mixture falls within this range.
    Silicone emulsifiers are preferred. Various silicone emulsifiers are useful herein. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants. Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing residues derived from ethylene oxide and propylene oxide. Other examples include alkyl-modified dimethicone copolyols, ie compounds containing C 2 -C 30 side chains. Still other useful dimethicone copolyols include materials having various cationic, anionic, zwitterionic and zwitterionic side groups.
    Dimethicone copolyol emulsifiers useful herein can be described by the following general formula:

    Where
    R is C 1 -C 30 straight, branched or cyclic alkyl,
    R 2 is — (CH 2 ) n —O— (CH 2 CHR 3 O) m —H and — (CH 2 ) n —O— (CH 2 CHR 3 O) m — (CH 2 CHR 4 O) o − Is selected from the group consisting of H,
    n is an integer from 3 to about 10,
    R 3 and R 4 are selected from the group consisting of H and C 1 -C 6 straight or branched alkyl, provided that R 3 and R 4 are not the same at the same time,
    m, o, x and y are independently selected from integers greater than or equal to 0, provided that m and o are not simultaneously 0
    z is independently selected from integers of 1 or more.
    Of course, positional isomers of these copolyols can be obtained. The above-described chemical expressions for R 2 residues containing R 3 and R 4 groups are not so restrictive but so are shown for convenience.
    Although not strictly classified as dimethicone copolyol, R 2 is-(CH 2 ) n -OR 5 in the general formula of the preceding paragraph, wherein R 5 is a cationic, anionic, zwitterionic or zwitterionic moiety Also useful herein are silicone surfactants.
    Non-limiting examples of dimethicone copolyols and other silicone surfactants useful herein as emulsifiers include polydimethylsiloxane polyether copolymers with polyethylene oxide side chains, polydimethylsiloxane polyether copolymers with polypropylene oxide side chains, mixed polyethylenes Polydimethylsiloxane polyether copolymer with oxide and polypropylene oxide side chain, polydimethylsiloxane polyether copolymer with mixed poly (ethylene) (propylene) oxide side chain, polydimethylsiloxane polyether aerial with organobetaine side chain The aforementioned air containing copolymers, polydimethylsiloxane polyether copolymers with carboxylate side chains, polydimethylsiloxane polyether copolymers with quaternary ammonium side chains, and C 2 -C 20 straight, branched or cyclic alkyl side groups There are variations of coalescing . Examples of commercially available dimethicone copolyols available herein available from Dow Corning Corporation include Dow Corning 190, 193, Q2-5220, 2501 Wax, 2-5324 Fluid, and 3225C (this material is associated with cyclomethicone). Commercially available as a mixture). Cetyl dimethicone copolyol is commercially available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and tradename ABIL® WE-09 (available from Goldschmidt) Commercially available. Cetyl dimethicone copolyols are also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and under the trade name ABIL WS-08 (available from Goldschmidt). Commercially available. Other non-limiting examples of dimethicone copolyols include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl Ethers, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate and dimethicone copolyol stearate. See International Cosmetic Ingredient Dictionary, 5th Edition, 1993, which is hereby incorporated by reference in its entirety.
    Dimethicone copolyol emulsifiers useful herein are described, for example, in US Pat. No. 4,960,764 to Figueroa, Jr. et al., Dated Oct. 2, 1990, the entirety of which is incorporated herein by reference; European Patent No. 330,369, published on August 30, 1989, in the name of Sano Gueira; G. H. Dahms et al., "New Formulation Possibilities Offered by Silicone Copolyols", Cosmetics & Toiletries, vol. 110, pp. 91-100, March 1995]; M. E. Carlotti et al., "Optimization of W / O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties", J. Dispersion Science And Technology, 13 (3), pp. 315-336 (1992); P. Hameyer, "Comparative Technological Investigations of Organic and Organosilicone Emulsifiers in Cosmetic Water-in-Oil Emulsion Preparations", HAPPI 28 (4), pp. 88-128 (1991); J. Smid-Korbar et al., "Efficiency and usability of silicone surfactants in emulsions", Provisional Communication, International Journal of Cosmetic Science, 12, pp. 135-139 (1990); And in D. G. Krzysik et al., “A New Silicone Emulsifier For Water-in-Oil Systems”, Drug and Cosmetic Industry, vol. 146 (4) pp. 28-81 (April 1990).
    Useful for the present silicon-ratio esters and polyesters, alkoxylated esters and polyesters, C 1 -C 30 fatty alcohols of C 1 -C 30 per acylated sugar-containing emulsifier in a fatty acid ester, C 1 -C 30 fatty alcohols of C 1 - Alkoxylated derivatives of C 30 fatty acid esters, Alkoxylated ethers of C 1 -C 30 fatty alcohols, Polyglyceryl esters of C 1 -C 30 fatty acids, C 1 -C 30 esters of polyols, C 1 -C 30 ethers of polyols Various nonionic and anionic emulsifiers are useful, such as, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof. Other suitable emulsifiers are described, for example, in McCutcheon, Detgents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation; US Patent No. 5,011,681 to Ciotti et al. On April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al. On December 20, 1983; And US Pat. No. 3,755,560, issued to Decourt et al. On August 28, 1973.
    Non-limiting examples of these silicone-free emulsifiers include polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steraate-20, ceteareth-20, PPG-2 methyl glucose Ether distearate, cetate-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG-100 stearate, polyoxyethylene 20 sorbitan Trioleate (polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, stearet-20, cetearete-20 , PPG-2 methyl glucose ether distearate, cetet-10, diethanolamine cetyl phosphate, glyceryl stearate, PEG-100 stearate There is a rate, and mixtures thereof.
    b) oil-in-water emulsions
    Other preferred topical carriers are oil-in-water emulsions having a continuous water phase and a dispersed hydrophobic water insoluble phase (“oil phase”). Particularly preferred oil-in-water emulsions containing a constituent, a hydrophilic surfactant and water are described in detail below.
    (i) constituents
    Preferred oil-in-water emulsions include a constituent that aids in the formation of the liquid crystal gel network. The concentration of such constituents is from about 1% to about 20%, preferably from about 1% to about 10%, more preferably from about 3% to about 9% by weight of the topical carrier.
    The appropriate configuration is a melting point of about 45 ℃ or more, a saturated C 16 -C 30 fatty alcohol, from about 1 to saturated containing ethylene oxide of from about 5 mole C 16 -C 30 fatty alcohols, saturated C 16 -C 30 diols, saturated C 16 -C 30 monoglycerol ether, saturated C 16 -C 30 hydroxy fatty acid and mixtures thereof.
    Preferred constituents include stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ethers of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, an average of about 1 to about 5 ethylene Polyethylene glycol ethers of cetyl alcohol with oxide units and mixtures thereof. More preferred constituents of the present invention are stearyl alcohol, cetyl alcohol, behenyl alcohol, polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (stearet-2), average of about 2 ethylene oxide units It is selected from the group consisting of polyethylene glycol ethers of cetyl alcohol having a mixture thereof. Even more preferred constituents are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, stearet-2 and mixtures thereof. Most preferred is Stearet-2, available under the trade name Brij® 72 from ICI Americas.
    (ii) hydrophilic surfactants
    Preferred oil-in-water emulsions contain from about 0.05% to about 10%, preferably from about 1% to about 6%, more preferably from about 1% to about 3, of one or more hydrophilic surfactants capable of dispersing hydrophobic materials in the aqueous phase. % By weight (based on the weight of the topical carrier). The surfactant should be at least hydrophilic enough to disperse in water.
    Suitable surfactants include various known cationic, anionic, zwitterionic and zwitterionic surfactants. McCurtchen, Detgents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation, hereby incorporated by reference in its entirety; U.S. Patent 5,011,681; US Patent No. 4,421,769; And US Pat. No. 3,755,560.
    The exact surfactant chosen will depend on the pH and other components of the composition.
    Preferred are cationic surfactants, in particular dialkyl quaternary ammonium compounds, examples of which are described in U.S. Patent Nos. 5,151,209; US Patent No. 5,151,210; US Patent No. 5,120,532; U.S. Patent 4,387,090; US Patent No. 3,155,591; US Patent No. 3,929,628; US Patent No. 3,959,461; McConcheon, Detergents and Emulsifiers, North American Edition (1979), M. C. Publishing Co .; And Schwartz et al., Surface Active Agents, Their Chemistry and Technology, New York: Interscience Publishers, 1949. Cationic surfactants useful herein include cationic ammonium salts such as compounds of the formula:

    Where
    R 1 is an alkyl group of about 12 to about 30 carbon atoms or an aromatic, aryl or alkaryl group of about 12 to about 30 carbon atoms;
    R 2 , R 3 and R 4 are hydrogen, alkyl groups of about 1 to about 22 carbon atoms or independently selected from aromatic, aryl or alkaryl groups of about 12 to about 22 carbon atoms;
    X is any compatible anion, preferably chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate and mixtures thereof It is selected from the group consisting of.
    In addition, the alkyl groups of R 1 , R 2 , R 3 and R 4 may also contain ester and / or ether linkage groups, or hydroxy or amino group substituents (eg, alkyl groups contain polyethylene glycol and polypropylene glycol moieties). You can).
    More preferably, R 1 is an alkyl group of about 12 to about 22 carbon atoms, R 2 is selected from H or an alkyl group of about 1 to about 22 carbon atoms, and R 3 and R 4 are H or about 1 to about carbon atoms. Independently selected from alkyl groups of 3, X is as defined above.
    Most preferably, R 1 is an alkyl group of about 12 to about 22 carbon atoms, R 2 , R 3 and R 4 are selected from H or an alkyl group of about 1 to about 3 carbon atoms, and X is as described above.
    Alternatively, other useful cationic emulsifiers include those in which R 1 is optionally R 5 CONH— (CH 2 ) n wherein R 5 is an alkyl group having from about 12 to about 22 carbon atoms, and n is about 2 To an integer from about 6, more preferably an integer from about 2 to about 4, most preferably an integer from about 2 to about 3.). Non-limiting examples of such cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) Ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate and mixtures thereof. Behenamidopropyl PG dimonium chloride is particularly preferred.
    Non-limiting examples of quaternary ammonium salt cationic surfactants include cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium Bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl Trimethyl Ammonium Chloride, Stearyl Trimethyl Ammonium Bromide, Lauryl Dimethyl Ammonium Chloride, Stearyl Dimethyl Cetyl Ditallow Dimethyl Ammonium Chlora Dide, Dicetyl Ammonium Chloride, Dicetyl Ammonium Bromide, Dilauryl Ammonium Chloride, Dilauryl Ammonium Bromide, Distearyl Ammonium Chloride, Distearyl Ammonium Bromide, Detyl Methyl Ammonium Chloride, Detyl Methyl Ammonium Bromide, Dilauryl Methyl Ammonium Chloride, dilauryl methyl ammonium bromide, distearyl methyl ammonium chloride, distearyl methyl ammonium bromide and mixtures thereof. Further quaternary ammonium salts are those in which the C 12 -C 30 alkyl carbon chain is derived from tallow fatty acids or coconut fatty acids. The term "tallow" refers to an alkyl group derived from tallow fatty acid (generally hydrogenated tallow fatty acid), which generally has a mixture of alkyl chains in the C 16 -C 18 range. The term "coconut" refers to an alkyl group derived from coconut fatty acid, which generally has a mixture of alkyl chains in the range of C 12 -C 14 . Examples of quaternary ammonium salts derived from such tallow and coconut raw materials include dallow dimethyl ammonium chloride, dallow dimethyl ammonium methyl sulfate, di (hydrogenated tallow) dimethyl ammonium chloride, di (hydrogenated tallow) dimethyl ammonium acetate, ditallow Dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, di (coconutalkyl) dimethyl ammonium chloride, di (coconutalkyl) dimethyl ammonium bromide, tallow ammonium chloride, coconut ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, Stearamidopropyl Ethyldimonium Ethosulfate, Stearamidopropyl Dimethyl (Mythyl Acetate) Ammonium Chloride, Stearamidopropyl Dimethyl Cetaryl Ammonium Tosylate, Stearamidopropyl Dimethyl Ammonium Chloride , Stearic amido there is propyl dimethyl ammonium lactate, and mixtures thereof. An example of a quaternary ammonium compound having an ester linked alkyl group is diethayl oxyethyl dimethyl ammonium chloride.
    More preferred cationic surfactants are behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, Stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldiammonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl Dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate and mixtures thereof.
    Most preferred cationic surfactants are in the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride and mixtures thereof It is chosen.
    Preferred combinations of cationic surfactants and constituents are behenamidopropyl PG dimonium chloride and / or behenyl alcohol, the ratios being physical and especially when the combination contains ionic and / or very polar solvents. It is desirable to be optimized to continue to enhance chemical stability. This combination is particularly useful for delivering sunscreen agents such as zinc oxide and octyl methoxycinnamate.
    Various anionic surfactants are also useful herein. See, for example, US Pat. No. 3,929,678 to Laughlin et al., Issued December 30, 1975, which is hereby incorporated by reference in its entirety. Non-limiting examples of anionic surfactants are alcoholic isethionates and their alkyl sulfates and alkyl ether sulfates. Alcoyl isethionates typically have the formula RCO-OCH 2 CH 2 SO 3 M (wherein R is alkyl or alkenyl of about 10 to about 30 carbon atoms, and M is ammonium, sodium, potassium and triethanolamine Water soluble cation). Non-limiting examples of such isethionates include alcohols selected from the group consisting of ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, and mixtures thereof. Isethionate.
    Alkyl sulfates and alkyl ether sulfates typically have the formula ROSO 3 M and the formula RO (C 2 H 4 O) x SO 3 M, respectively, wherein R is alkyl or alkenyl having from about 10 to about 30 carbon atoms, and x is From about 1 to about 10, M is a water soluble cation such as ammonium, sodium, potassium and triethanolamine. Another suitable anionic surfactant class is the water-soluble salt of the organic sulfuric acid reaction product of the general formula R 1 -SO 3 -M (wherein R 1 is a straight chain of about 8 to about 24 carbon atoms, preferably about 10 to about 16 carbon atoms or Branched, saturated aliphatic hydrocarbon radicals, M is a cation). Still other anionic synthetic surfactants include those called succinamate, olefin sulfonates having about 12 to about 24 carbon atoms, and β-alkyloxy alkanes sulfonates. Examples of these materials are sodium lauryl sulfate and ammonium lauryl sulfate.
    Other anionic materials useful herein are typically soaps of fatty acids of about 8 to about 24 carbon atoms, preferably about 10 to about 20 carbon atoms (ie, alkali metal salts such as sodium or potassium salts). Fatty acids used to make soaps can be obtained from natural sources such as, for example, glycerides derived from plants or animals (eg, palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc.). Fatty acids may be prepared synthetically. Soaps are described in more detail in US Pat. No. 4,557,853, cited above.
    Zwitterionic surfactants and zwitterionic surfactants are also useful herein. Examples of zwitterionic and zwitterionic surfactants that may be used in the compositions of the present invention include those wherein the aliphatic radicals may be straight or branched, and one of the aliphatic substituents has from about 8 to about 22 carbon atoms (preferably C 8 -C 18 ), broadly described as derivatives of aliphatic secondary and tertiary amines containing anionic water soluble groups (eg carboxy, sulfonate, sulfate, phosphate or phosphonate). Examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates of the formulas RN [(CH 2 ) m CO 2 M] 2 and RNH (CH 2 ) m CO 2 M, wherein m is 1 To 4, R is C 8 -C 22 alkyl or alkenyl, and M is H, alkali metal, alkaline earth metal ammonium or alkanol ammonium. Also included are imidazolinium and ammonium derivatives. Specific examples of suitable zwitterionic surfactants include sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopropane sulfonate, N-alkyltaurine (e.g., U.S. Pat. Prepared by reacting dodecylamine with sodium isethionate according to the teachings of 2,658,072); N-higher alkyl aspartic acids (eg, prepared according to the teachings of US Pat. No. 2,438,091, which is incorporated herein by reference in its entirety); And the product described in US Pat. No. 2,528,378, which is commercially available under the trade name " Miranol ", which is incorporated herein by reference in its entirety. Other examples of useful zwitterionic materials are phosphates such as coamidopropyl PG-dimonium chloride phosphate (commercially available as Monaquat PTC from Mona Corp.).
    Also useful herein as zwitterionic or zwitterionic surfactants are betaines. Examples of betaines include coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine [Lonza Corp. from Lonza Corp.] (Lozaine) available as 16SP], lauryl bis- (2-hydroxyethyl) carboxymethyl betaine, stearyl bis- (2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine , Lauryl bis- (2-hydroxypropyl) alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis- (2-hydroxy Oxyethyl) sulfopropyl betaine, and amidobetaine and amidosulfobetaine [RCONH (CH 2 ) 3 radicals are bound to the nitrogen atom of betaine], oleyl betaine from Henkel Available as zwitterionic Velvetex OLB-50], and higher alkyl betaines such as cochamidopropyl betaine (available as Belvetex BK-35 and BA-35 from Henkel).
    Other useful zwitterionic and zwitterionic surfactants include salts and hydrides, such as cochamidopropyl hydrosulfite (available as Mirataine CBS from Rhone-Poulenc). Loxultine, and the formula RCON (CH 3 ) CH 2 CH 2 CO 2 M, wherein R is alkyl or alkenyl having about 10 to about 20 carbon atoms, and M is ammonium, sodium, potassium and trialkanolamine (e.g., And a water-soluble cation), such as triethanolamine), and a preferred example thereof is sodium lauroyl sarcosinate.
    (iii) water
    Preferred oil-in-water emulsions comprise water from about 25% to about 98%, preferably from about 65% to about 95%, more preferably from about 70% to about 90% by weight of the topical carrier.
    The hydrophobic phase is dispersed in the continuous water phase. The hydrophobic phase may contain water insoluble or partially water soluble materials, such as those known in the art, including but not limited to the silicones described herein for the silicone-in-water emulsion, and other fats described above for the emulsion. .
    Topical compositions of the present invention, including but not limited to lotions and creams, may also include dermatologically acceptable emollients. Such compositions preferably contain about 2% to about 50% emollients. As used herein, the term "skin emollient" refers to a substance useful for protecting the skin as well as preventing or alleviating skin drying. Various suitable emollients are known and can be used herein. Sagarin, incorporated herein by reference, Cosmetics, Science and Technology, 2nd edition, Vol. 1, pp. 32-43 (1972) illustrate a number of materials suitable as emollients. Preferred emollients are glycerin. Glycerin is preferably used at from about 0.001% to about 20%, more preferably from about 0.01% to about 10%, most preferably from about 0.1% to about 5% (eg 3%).
    Lotions and creams according to the present invention generally comprise a solution carrier system and one or more emollients. The lotion typically contains about 1% to about 20%, preferably about 5% to about 10% emollients; About 50% to about 90%, preferably about 60% to about 80% of water; And vitamin B 3 compounds in the amounts described above. Creams typically range from about 5% to about 50%, preferably from about 10% to about 20% emollients; About 45% to about 85%, preferably about 50% to about 75% of water; And vitamin B 3 compounds in the amounts described above.
    Ointments according to the present invention may comprise simple carrier bases of animal or vegetable oils or semisolid hydrocarbons (oily); An absorbent ointment base that absorbs water to form an emulsion; Or a water soluble carrier (eg, a water soluble solution carrier). Ointments are described in Sagarin, Cosmetics, Science and Technology, 2nd edition, Vol. 1, pp. 72-73 (1972), and may further include thickeners, and / or emollients. For example, the ointment may contain about 2% to about 10% emollients; About 0.1% to about 2% of a thickener; And vitamin B 3 compounds in amounts described above.
    Compositions ("cleaners") of the invention useful for washing are formulated, for example, with a suitable carrier as described above, in addition to the aforementioned amounts of the vitamin B 3 compound, a dermatologically acceptable surfactant from about 1 to about 90%, more preferably Preferably about 5 to about 10%. The surfactant is suitably selected from the group consisting of anionic, nonionic, zwitterionic, zwitterionic surfactants and mixtures thereof. Such surfactants are well known to those skilled in the detergent field. Non-limiting examples of possible surfactants include isocetate-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate and sodium lauryl sulfate. See US Pat. No. 4,800,197, issued to Kowcz et al. On January 24, 1989, which is incorporated herein by reference in its entirety for examples of surfactants useful herein. Extensive examples of additional surfactants useful herein are described in McCutcheon's Detergents and Emulsifiers, North American Edition, 1986, Allured Publishing Corporation, which is incorporated herein by reference in its entirety. The cleaning composition may optionally contain other materials conventionally used in the cleaning composition in amounts determined in the art.
    The physical form of the cleaning composition is not critical. The composition may be formulated, for example, as a bath bar, liquid, shampoo, wood gel, hair conditioning agent, hair tonic, paste or mousse. Most preferred is the bathroom bar since it is in the form of a detergent most commonly used to clean skin. Rinsing cleaning compositions (such as shampoos) require a delivery system suitable for depositing a sufficient amount of action on the skin and scalp. Preferred delivery systems include the use of insoluble complexes. For more detailed literature on such delivery systems, see US Pat. No. 4,835,148, issued to Barford et al. On May 30, 1989, which is incorporated herein by reference in its entirety.
    As used herein, the term "powder" refers to liquid, semi-liquid, semi-solid or solid skin cosmetics, including but not limited to lotions, creams, gels, pastes, cakes, and the like. Foundations are typically used on large areas of the skin, such as the entire face, to provide a unique look. Foundations are typically used to provide a sticky base for color cosmetics such as rouge, blusher, powder, and the like, concealing skin flaws and making the appearance of the skin smooth and uniform. The foundation of the present invention includes a dermatologically acceptable carrier for a vitamin B 3 compound and may include conventional ingredients such as oils, colorants, pigments, emollients, perfume oils, waxes, stabilizers and the like. Exemplary carriers suitable for use herein and such other components are co-pending patents filed April 28, 1995 in the name of Marcia L. Canter, Barford and Brain D. Hofrichter. No. 08 / 430,961, which is incorporated herein by reference.
    The composition of the present invention is preferably formulated to have a pH of less than 10.5. The pH value of this composition is preferably about 2 to about 10.5, more preferably about 3 to about 8, even more preferably about 4 to about 7, most preferably about 4.5 to about 5.5.
    Optional ingredients
    Topical compositions of the present invention may include a wide variety of optional ingredients so long as they are physically and chemically compatible with the essential ingredients described herein and do not unduly impair the stability, efficacy or other benefits of use associated with the compositions of the present invention. Can be. Any optional ingredient should be compatible with the vitamin B 3 compound such that the activity of the vitamin B 3 compound is not tolerated, preferably to a significant extent, over the useful period (preferably about two years or more under standard storage conditions). do. For example, strong oxidants may be incompatible with vitamin B 3 compounds and such oxidants are preferably avoided. Optional components may be dispersed or dissolved in the carrier of the composition.
    Optional ingredients include cosmetic drugs and other active ingredients. For example, the composition may include absorbents, abrasives, dispersants, antifoams, fungicides, binders, biological additives, buffers, swelling agents, chemical additives, chemical fungicides, denaturants, chemical astringents, drug astringents, skin analgesics, membrane formers, humectants, milk whitening agents. , Antiseptics, pigments, colorants, essential oils, skin sensitizers, emollients, skin calming agents, skin treatments, pH adjusters, plasticizers, preservatives, antiseptics, propellants, reducing agents, additional skin conditioners, skin penetration enhancers, skin protectants, solvents, suspensions Agents, emulsifiers, thickeners, solubilizers, sunscreens, ultraviolet absorbers or scattering agents, sunless tanning agents, antioxidants and / or radical scavengers, chelating agents, sequestrants, anti-inflammatory agents, anti-inflammatory agents, Androgen inhibitors, hair loss agents, dermabrasion agents, organic hydroxy acids, vitamins and derivatives thereof, and natural extracts. Such other materials are known in the art. Non-exclusive examples of such materials are described in Harry's Cosmeticology, 7th Ed., Harry & Wilkinson, Hill Publishers, London, 1982; Pharmaceutical Dosage Forms- Disperse Systems; Lieberman, Rieger & Banker, Vols. 1 (1988) & 2 (1989), Marcel Decker, Inc .; The Chemistry and Manufacture of Cosmetics, 2nd. Ed., DeNavarre, Van Nostrand, 1962-1965; And The Handbook of Cosmetic Science and Technology, 1st Ed., Knowlton & Pearce, Elsevier, 1993.
    It has been found that some compounds can negatively affect the benefits of skin appearance provided by vitamin B 3 compounds. Such compounds include ascorbic acid and N-acetyl cysteine. Without wishing to be bound by theory, it appears that these compounds can form large complexes (such as salts) with vitamin B 3 compounds, reducing the availability of vitamin B 3 compounds to the skin. Such complexes appear to have relatively high molecular weights that reduce their availability to the skin. Thus, in one aspect of the invention the composition does not contain compound (s) capable of forming large complexes similar to vitamin B 3 compounds. In another embodiment, for compositions containing said compound (s) capable of forming large complexes with vitamin B 3 compounds, one or more of the methods described herein above may be used to minimize or prevent the formation of undesirable complexes. desirable.
    For example, the effect of the compound on the efficacy of the vitamin B 3 compound decreases with decreasing pH, so the pH can be adjusted to minimize or avoid the result. For example, when the composition contains N-acetyl-L-cysteine, the pH of the composition is preferably adjusted to about 2 to about 5, more preferably about 3 to about 4. PH adjustments to avoid substantive effects on efficacy are at a level known to those of ordinary skill in the art.
    Specific examples of optional components are as follows. Active ingredients useful herein are classified by the benefit of their makeup and / or treatment, or by the desired action. However, it is understood that the active ingredients useful herein may in some cases provide the benefit of one or more cosmetic and / or therapeutic or be operated by one or more acts. Thus, classifications herein are for convenience and are not intended to limit the active ingredient to the specific use (s) listed.
    A. Anti-inflammatory
    Anti-inflammatory agents may be added to the compositions of the present invention in a safe effective amount, preferably from about 0.1 to about 10%, more preferably from about 0.5 to about 5% of the composition. Anti-inflammatory agents increase the benefits of the skin appearance of the present invention, for example anti-inflammatory agents provide a more uniform and acceptable skin tone or color. The exact amount of anti-inflammatory agent used in the composition depends on the particular anti-inflammatory agent used because the anti-inflammatory agent varies greatly in efficacy.
    Steroidal anti-inflammatory agents such as hydrocortisone, hydroxyltriamcinolone, α-methyl dexamethasone, dexamethasone-phosphate, beclomethasone, dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticos Theron acetate, dexamethasone, dichlorisone, diflorasone, diacetate, diflucortolone valerate, fluadenolone, fluclolone acetonide, fludrocortisone, flumethasone pivalate, fluorcinolone acetonide, Fluorininide, Flucortin Butyl Ester, Fluorocortolone, Flufrednidene (Flufrednilidene) Acetate, Fluandrenolone, Halcinonoid, Hydrocortisone Acetate, Hydrocortisone Butyrate, Methylprednisolone, Triamcinolone Acetonide, Cortisone , Cortodoxone, flucetonide, flu Drocortisone, difluoroson diacetate, fluadrenolone, fludrocortisone, difluroson diacetate, fludrenolone acetonide, medridone, amcinofel, amcinamide, betamethasone and the remaining esters, chloroprednisone , Chlorprednisone Acetate, Clocortelone, Clecinolone, Dichlorisone, Diflurfredate, Fluchloronide, Flunisoleide, Fluorometallon, Fluperolone, Fluprednisolone, Hydrocortisone valerate, Hydrocortisone cyclo Corticosteroids such as pentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone and mixtures thereof can be used, but are not limited to these. . Preferred steroidal anti-inflammatory agents for use are hydrocortisone.
    The second class of anti-inflammatory agents useful in the present compositions includes nonsteroidal anti-inflammatory agents. Various compounds included in this class are sufficiently known to those skilled in the art. For a detailed description of the chemical structure, synthesis and side effects of nonsteroidal anti-inflammatory drugs, see Anti-inflammatory and Anti-Rheumatic Drugs, K.D. Rainsford, Vol. I-III, CRC Press, Boca Raton (1985) and Anti-inflammatory Agents, Chemistry and Pharmacology, 1. RAScherrer et al., Academic Press, New York, 1974. Are each incorporated herein by reference.
    Specific nonsteroidal anti-inflammatory agents useful in the present compositions include, but are not limited to:
    1) Oxycam, such as pyroxicam, isoxicam, tenoxycam, sudoxicam, and CP-14,304;
    2) salicylates such as aspirin, dissalside, benolylate, trilysate, sapapurin, sulphrine, diflunisal and pendosal;
    3) diclofenac, fenclofenac, indomethacin, sulindac, tolmethine, isoxepac, propenac, thiopinac, dozmethacin, acematacin, pentiazac, jomepirak, clindac, oxepinac, Acetic acid derivatives such as felbinac and ketorolac;
    4) phenamate, such as mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid;
    5) Ibuprofen, Naproxen, Benoxapropene, Flurobiprofen, Ketoprofen, Phenopropene, Penbufen, Indoprofen, Pirprofen, Caprofen, Oxaprozin, Pranoprofen, Miroprofen Propionic acid derivatives such as phen, thioxapropene, suprofen, aminopropene and thiapropenic; And
    6) pyrazoles such as phenylbutazone, oxyphenbutazone, peprazone, azapropazone and trimetazone.
    Mixtures of these nonsteroidal anti-inflammatory agents as well as dermatologically acceptable salts and esters of these anti-inflammatory agents may be used. For example, etophenamate, a flufenamic acid derivative, is particularly useful for topical application. Among the nonsteroidal anti-inflammatory agents, isobufen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, pyroxicam and felbinac are preferred, and isobufen, naproxen, etofenamate, aspirin and flu Phenolic acid is most preferred.
    Finally, so-called "natural" anti-inflammatory agents are useful in the methods of the present invention. Such anti-inflammatory agents may be suitably obtained as extracts by appropriate physical and / or chemical isolation from natural raw materials (eg by-products of plants, fungi, microorganisms). For example, candelilla wax, α-bisabolol, aloe vera, Manzistar (extracted from Rubia genus, in particular Rubia Cordifolia genus) and gugal (Commiphora genus, in particular Komi) Extracted from plants of the genus Commiphora Mukul), cola extract, chamomile and sea whip extract can be used.
    Additional anti-inflammatory agents useful herein include compounds with licorice (Glycyrrhiza glabra) / Glycyrrhiza glabra, including glycyrrhetic acid, glycyrrhizic acid and derivatives thereof such as salts and esters. . Suitable salts of the foregoing compounds include metal and ammonium salts. Suitable esters include C 2 -C 24 , preferably C 10 -C 24 , more preferably C 16 -C 24 saturated or unsaturated esters of acids. Specific examples of the above-mentioned compounds include fat soluble licorice extract, glycyrrhizic acid, glycyrrhetic acid, monoammonium glycyrginate, monopotassium glycyrginate, dipotassium glycyrginate, 1-β-glysiretic acid , Stearyl glycyrrhetinate, 3-stearyloxy-glycithinhetic acid and disodium-3-succinyloxy-β-glyciherinate. Stearyl glycyrrhetinate is preferred.
    B. Retinoids
    In a preferred embodiment, the composition of the present invention also contains a retinoid. Vitamin B 3 compounds and retinoids provide unexpected benefits in regulating skin conditions, particularly in the treatment of signs of skin aging, more specifically in wrinkles, lines and pores. Without being bound by theory, vitamin B 3 compounds appear to synergistically regulate skin conditions by increasing the conversion of some retinoids to trans-retinoic acid, which appears to be the biologically active form of retinoids (ie, retinol, retinol esters and Increased conversion to retinal). In addition, vitamin B 3 compounds relieve erythema, inflammation, and dermatitis (hereafter referred to as “retinoid dermatitis”, sometimes referred to as this), which may unexpectedly be associated with topical application of retinoids. In addition, the binding of the vitamin B 3 compound and the retinoid is easy to increase the amount of thioredoxin active, thereby increasing the degree of collagen expression through the protein AP-1. Thus, the present invention can reduce the amount of activity and thus reduce the efficacy for retinoid dermatitis, while maintaining a fairly certain skin control advantage. In addition, large amounts of retinoids can be used to obtain greater skin control efficacy without causing undesirable retinoid dermatitis.
    As used herein, "retinoid" includes both natural and / or synthetic homologs of vitamin A or retinol compounds having the biological activity of vitamin A as well as the geometric and stereoisomers of this compound in the skin. Retinoids are preferably retinol, retinol esters (e.g., C 2 -C 22 alkyl esters of retinol including retinyl palmitate, retinyl acetate, retinyl propionate), retinal and / or retinoic acid (all trans Retinoic acid and / or 13-cis retinoic acid), more preferably retinoids other than retinoic acid. These compounds are well known to those skilled in the art and are available from various sources, such as Sigma Chemical Co., St. Louis, Missouri, USA, and Boerhinger Mannheim, Indianapolis, Indiana, USA. Other retinoids useful herein include U.S. Patent No. 4,677,120 issued to Parisi et al. On June 30, 1987, U.S. Patent No. 4,885,311 to Parisi et al. On December 5, 1989, 9 1991. US Patent No. 5,049,584 to Purcell et al. On May 17, US Patent No. 5,124,356 to Purcell et al. On June 23, 1992, and Purse et al. On September 22, 1992 No. 34,075, incorporated herein by reference. Other suitable retinoids are tocopherol-retinoate [tocopherol ester of retinoic acid (trans- or cis-), adapalene {6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid} And tazarotene (ethyl 6- [2- (4,4-dimethylthiochroman-6-yl) -ethynyl] nicotinate). One or more retinoids can be used herein. Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and mixtures thereof. Retinol and retinyl palmitate are more preferred.
    Retinoids may be included as substantially pure substances or as extracts obtained by suitable physical and / or chemical isolation from natural (eg plant) sources. The retinoid is preferably substantially pure and more preferably essentially pure.
    Since the compositions of the present invention contain a safe effective amount of retinoids, the resulting compositions control skin conditions, preferably to control the visible and / or tactile discontinuities of the skin, more preferably to control signs of skin aging. And even more preferably safe and effective in controlling the visible and / or tactile discontinuity of skin tissue associated with skin aging. The composition preferably contains about 0.005 to about 2%, more preferably 0.01 to about 2% of the retinoid. Retinol is most preferably used in amounts of about 0.01 to about 0.15%, retinol esters are most preferably used in amounts of about 0.01 to about 2% (eg, about 1%), and retinoic acid is most preferably about 0.01 Tocopheryl-retinoate [tocopherol of retinoic acid (trans- or cis-), adapalene {6- [3- (1-adamantyl) -4-methoxyphenyl]- 2-naphthoic acid}, and tazarotene are most preferably used in amounts of about 0.01 to about 2%. If the composition contains a retinoid, the vitamin B 3 compound is preferably used in an amount of about 0.1 to about 10%, more preferably about 2 to about 5%.
    C. Antibacterial
    As used herein, "antimicrobial agent" means a compound capable of destroying microorganisms, preventing the expansion of microorganisms or preventing the pathological action of microorganisms. Antibacterial agents are useful for example in inhibiting acne. The antimicrobial agent is a safe effective amount, preferably from about 0.001 to about 10%, more preferably from about 0.01 to about 5%, most preferably from about 0.05 to about 2% or from about 0.05 to about 1% of the composition of the present invention. Can be added to. Preferred antibacterial agents useful in the present invention are benzoyl peroxide, erythromycin, tetracycline, cyclamycin, azelaic acid and sulfur resorcinol.
    D. Androgen Inhibitors
    As used herein, "androgen inhibitor" refers to a compound that can correct for androgen-related disorders by interfering with androgen action in target tissues. The target tissue of the present invention is the skin of a mammal. Exemplary androgen inhibitors include pregnenalon (and derivatives thereof), hop extracts, oxygenated alkyl-substituted bicyclic alkanes (e.g., ETHOCYN and CYOCTOL from Chantal Pharmaceutical, Los Angeles, CA, USA). Commercially available ethoxyhexyl-bicyclo octanone, and 2- (5-ethoxy hept-1-yl) bicyclo [3.3.1] octanone), and olenolic acid. Suitable androgen inhibitors are described in US Pat. Nos. 4,689,345 and 4,855,322, issued to Kasha et al. On August 25, 1987 and August 8, 1989, respectively, which references are herein incorporated by reference. It is cited in the literature.
    E. Sunscreens
    Ultraviolet exposure can cause excessive peeling and tissue changes of each layer. Therefore, the composition of the present invention preferably contains a sunscreen agent. Suitable sunscreens can be organic or inorganic compounds.
    A wide variety of conventional sunscreens are suitable for use herein. Sagarin et al. (Cosmetics Science and Technology (1972), Chapter VIII, pages 189 and later) disclose a number of suitable sunscreens, which are incorporated herein by reference. Specific suitable sunscreen agents include, for example, p-aminobenzoic acid and salts thereof and derivatives thereof (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid); Anthranilates (ie o-amino-benzoate; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terfinyl and cyclohexenyl esters); Salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl and di-propylene glycol esters); Cinnamic acid derivatives (mentyl and benzyl esters. Α-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); Dihydroxycinnamic acid derivatives such as umbelliferone, methylumbelliferone, methylaceto-umbelliferone); Trihydroxy-cinnamic acid derivatives such as esculintin, methylesculletin, daphnetine, glucoside, esculin and daphnin; Hydrocarbons such as diphenylbutadiene, stilbene; Dibenzalacetone and benzalacetophenone; Naphtholsulfonate (eg, the sodium salt of 2-naphthol-3,6-disulfonic acid and 2-naphthol-6,8-disulfonic acid); Di-hydroxynaphthoic acid and salts thereof; o- and p-hydroxybiphenyldisulfonates; Coumarin derivatives such as 7-hydroxy, 7-methyl, 3-phenyl; Diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthazole, various aryl benzothiazoles); Quinine salts such as bisulfate, sulfate, chloride, oleate and tannate; Quinoline derivatives such as 8-hydroxyquinoline salt, 2-phenylquinoline; Hydroxy- or methoxy-substituted benzophenones; Uric acid and viluic acid; Tannic acid and its derivatives such as hexaethyl ether; (Butylcarbotol) (6-propyl piperonyl) ether; Hydroquinone; Benzophenone (oxybenzene, sulfisobenzone, dioxybenzone, benzoresorcinol, 2,2 ', 4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'- Dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane; etocrylene; octocrylene; [3- (4'-methylbenzylidene bornan-2-one) and 4- Isopropyl-di-benzoylmethane.
    2-ethylhexyl-p-methoxycinnamate (commercially available as PASOL MCX), 4,4'-t-butyl methoxydibenzoyl-methane (commercially available as parsol 1789), 2-hydride Hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digaloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4- (bis (hydroxy-propyl )) Aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl salicylate, glyceryl-p-aminobenzoate, 3,3,5-tri- Methylcyclohexylsalicylate, methylanthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl-amino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2 Preference is given to-(p-dimethylaminophenyl) -5-sulfonbenzoxazoic acid, octocrylene and mixtures thereof.
    More preferred organic sunscreens for use in the compositions useful in the present invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-4-methoxybenzo-phenone, 2-phenylbenz Imidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene and mixtures thereof.
    Also, as described in US Pat. No. 4,937,370 issued to Sabatelli, June 26, 1990 and US Pat. No. 4,999,186, issued to Sabatelli and Spinark, March 12, 1991. Sunscreens are particularly useful in the present compositions, both of which are incorporated herein by reference. The sunscreens disclosed in this document have two unique chromophore moieties that exhibit different ultraviolet absorption spectra in a single molecule. One of the chromophore residues is mainly absorbed in the UVB range and the other is strongly absorbed in the UVA range.
    Preferred members of this type of sunscreen agent are 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid esters of 2,4-dihydroxybenzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; 4-N, N- (2-ethylhexyl) -methylaminobenzoic acid ester of 4- (2-hydroxyethoxy) dibenzoylmethane; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of 4- (2-hydroxyethoxy) dibenzoylmethane; And mixtures thereof.
    Suitable inorganic sunscreens include metal oxides such as zinc oxide and titanium dioxide. For example, the use of titanium dioxide in topical sunscreen compositions that can be applied to the present invention is dated May 24, 1995 by Yugyu, Lisa R. Dew and Donald L. Bisett. Co-pending patent application No. 08 / 448,942, filed under the name of, which is incorporated herein by reference.
    Particularly preferred sunscreens include metal oxides such as zinc oxide and titanium dioxide; Butylmethoxydibenzoylmethane; 2-ethylhexyl-p-methoxycinnamate; Phenylbenzimidazole sulfonic acid; And octocrylene.
    Sunscreens are used in safe effective amounts, typically about 1 to about 20%, more typically about 2 to about 10%. The exact amount will vary depending on the sunscreen chosen and the desired Sun Protection Factor (SPF).
    In addition, sunscreens that increase the skin substantivity of the present compositions and prevent them from being rinsed or scrubbed, especially with water, can be added to any composition useful in the present invention. Preferred sunscreens that provide this advantage are copolymers of ethylene and acrylic acid. A composition comprising this copolymer is described in US Pat. No. 4,663,157, issued to Brock on May 5, 1987, which is incorporated herein by reference.
    F. Antioxidants / Radical Scavengers
    Preferred compositions of the present invention comprise an antioxidant / radical scavenger as the active ingredient in addition to the main active ingredient. Antioxidants / radical scavengers are particularly useful for protecting against UV rays, which can increase peeling or tissue changes in each layer, and other environmental agents that can cause skin damage.
    Antioxidants / radical scavengers may be added to the compositions of the present invention in a safe effective amount, preferably from about 0.1 to about 10%, more preferably from about 1 to about 5% of the composition.
    Ascorbic acid (vitamin C) and salts thereof, ascorbyl esters of fatty acids, ascorbic acid derivatives (such as magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, other esters of tocopherol, butylated hydroxy benzoic acid And salts thereof, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the trade name Trolox®), gallic acid and alkyl esters thereof, in particular propyl gal Rate, uric acid and salts thereof and alkyl esters, sorbic acid and salts thereof, amines such as N, N-diethylhydroxylamine, amino-guanidine, sulfhydryl compounds such as glutathione, dihydroxy fumaric acid and Salts thereof, lysine pydolate, arginine phylate, nordihydroguaiaretic acid, bioflavonoids, lysine, methionine, proline, superoxide dismutase, silymarin, tea extract, grape skin / seed extract, Antioxidants / radical scavengers may be used, such as melanin and rosemarine extracts. Preferred antioxidants / radical scavengers are selected from the group consisting of tocopherol sorbate and other esters of tocopherol, more preferably tocopherol sorbate. For example, the use of tocopherol sorbate in topical compositions that can be applied to the present invention is described in US Pat. No. 4,847,071 to Bisset, Bush and Chattersey, dated July 11, 1989. , Which is incorporated herein by reference.
    G. Chelating Agents
    As used herein, "chelating agent" refers to an active ingredient that can remove metal ions from a system by forming complexes so that metal ions do not readily participate in or accelerate the chemical reaction. The inclusion of chelating agents is particularly useful to provide protection against UV rays, which can cause excessive peeling and changes in skin tissue, and other environmental agents that can cause skin damage.
    Chelating agents may be added to the compositions of the present invention in a safe effective amount, preferably from about 0.1 to about 10%, more preferably from about 1 to about 5% of the composition. Examples of chelating agents useful herein are described in US Pat. No. 5,487,884 to Bisset et al. On Jan. 30, 1996; International Patent Application No. 91/16035, published by Bush et al. On October 31, 1995; And International Patent Application No. 91/16034, published October 31, 1995 to Bush et al., All of which are incorporated herein by reference. Preferred chelating agents useful in the compositions of the present invention are furyldioxime and derivatives thereof.
    H. Organic Hydroxy Acids
    The composition of the present invention preferably comprises an organic hydroxy acid. Suitable hydroxy acids include C 1 -C 18 , preferably C 8 or less hydroxy acids. Hydroxy acids can be substituted or unsubstituted, can be straight, branched or cyclic (preferably straight chain), and can be saturated or unsaturated (mono- or polyunsaturated) (preferably saturated). Non-limiting examples of suitable hydroxy acids include salicylic acid, glycolic acid, lactic acid, 5-octanoyl salicylic acid, hydroxyoctanoic acid, hydroxycaprylic acid and lanolin fatty acids. Preferred concentrations of organic hydroxy acids are from about 0.1 to about 10%, more preferably from about 0.2 to about 5%, even more preferably from about 0.5 to about 2%. Salicylic acid is preferred. Organic hydroxy acids enhance the skin appearance benefits of the present invention. For example, organic hydroxy acids are easy to improve skin tissue.
    I. Dermabrasion
    Dermabrasion is added to the compositions of the present invention in a safe effective amount, preferably from about 0.1 to about 10%, more preferably from about 0.2 to about 5%, most preferably from about 0.5 to about 4% of the composition. Dermabrasion enhances the skin appearance benefits of the present invention. For example, dermabrasives are easy to improve (eg, smooth) the skin's tissues. Various dermabrasion agents are known in the art and suitable for use herein, and examples include, but are not limited to, the organic hydroxy agents described above. One peeling system suitable for use herein includes a sulfhydryl compound and a zwitterionic surfactant, and corresponds to PCT patent US 95/08136, filed June 29, 1995, June 7, 1995. Which is described in co-pending patent application No. 08 / 480,632, filed in the name of a non-set date, each of which is incorporated herein by reference. Another peeling system suitable for use herein includes salicylic acid and zwitterionic surfactants and corresponds to PCT Application No. 94/12745, filed November 4, 1994 and published May 18, 1995. No. 08 / 209,401, filed March 9, 1994, in the name of Biset, described in co-pending patent application No. 08 / 554,944, filed Nov. 13, 1995, supra. Each is incorporated herein by reference. Zwitterionic surfactants described in this patent are also useful as the skinning agent herein, with cetyl betaine being particularly preferred.
    J. Hair Loss
    The composition of the present invention may comprise a safe effective amount of a depilatory agent. The composition preferably contains from about 0.1 to about 10%, more preferably from about 0.2 to about 5%, even more preferably from about 0.5 to about 2% of a hair loss agent in use. Preferred hair loss agents for use herein include sulfhydryl compounds such as N-acetyl-L-cysteine. The use of such adjuvants is in the name of Greg G. Hillebrand and Vladimir Gartstein, June 7, 1995, corresponding to PCT application US 95/07311, filed June 8, 1995. It is described in more detail in co-pending patent application No. 08 / 479,878, filed on a date, each of which is incorporated herein by reference.
    K. Skin Whitening Agent
    The composition of the present invention may comprise a skin lightening agent. In use, the composition preferably comprises about 0.1 to about 10%, more preferably about 0.2 to about 5%, even more preferably about 0.5 to about 2% of a skin lightening agent. Suitable skin lightening agents include compounds known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof such as magnesium ascorbyl phosphate. Skin whitening agents suitable for use herein are described in co-pending patent application filed June 7, 1995 in the name of Hillbrand, corresponding to PCT application US 95/07432, filed June 12, 1995. / 479,935; And Kalla L. Kvalnes, Mitchell A. DeLong, Barton, corresponding to PCT Application US 95/02809, filed March 1, 1995 and published September 8, 1995. Including those described in co-pending patent application Ser. No. 08 / 390,152, filed February 24, 1995, in the name of J. Bradbury, Curtis B, Motley, and John D. Carter. All documents are incorporated herein by reference.
    L. Zinc Salt
    The composition of the present invention may further comprise a zinc salt. Zinc salts are particularly preferred when the composition contains sulfhydryl compounds such as N-acetyl-L-cysteine. Without being bound by theory, zinc salts appear to act as chelating agents that can complex with sulfhydryl compounds prior to topical application and to stabilize the sulfhydryl compound and / or inhibit odors associated with sulfhydryl compounds. The concentration of zinc salt may be about 0.001 to about 10%, more preferably about 0.01 to about 5%, most preferably about 0.1 to about 0.5% by weight of the composition.
    Preferred zinc salts are zinc acetate, zinc acetate hydrates such as zinc acetate dihydrate, zinc aluminum oxide complexes such as ganite, zinc diamine, zinc antimonide, zinc bromate hydrates such as zinc bromate hexahydrate ), Zinc bromide, zinc carbonate (e.g. zinc spa and mittsonite), zinc chlorate hydrate (e.g. zinc chlorate tetrahydrate), zinc chloride, zinc diamine dichloride, zinc citrate, zinc chromate, zinc di Chromate, zinc diphosphate, zinc hexacyanofluoride ferrate (II), zinc fluoride, zinc fluoride hydrate (e.g. zinc fluoride tetrahydrate), zinc formate, zinc formate hydrate (e.g. zinc formate Dihydrate), zinc hydroxide, zinc iodide, zinc iodide hydrate (e.g. zinc iodide) Hydride dihydrate), zinc iodide, zinc oxide iron complex, zinc nitrate hydrate (e.g. zinc nitrate hexahydrate), zinc nitride, zinc oxalate hydrate (e.g. zinc oxalate dihydrate), zinc oxide (e.g. Zincsite), zinc perchlorate hydrate (e.g. zinc perchlorate hexahydrate), zinc permanganate hydrate (e.g. zinc permanganate hexahydrate), zinc peroxide, zinc p-phenolsulfonate hydrate (e.g. zinc p-phenol Sulfonate octahydrate), zinc phosphate, zinc phosphate hydrate (e.g. zinc phosphate tetrahydrate), zinc phosphide, zinc propionate, zinc selenate hydrate (e.g. zinc selenate pentahydrate), zinc selenide, zinc silicate (Eg zinc silicate (2) and zinc silicate (4)), zinc silicon oxide-water complex (eg hemimorphite), zinc hexafluorosilicate Hydrate (e.g. zinc hexafluorosilicate hexahydrate), zinc stearate, zinc sulphate, zinc sulphate hydrate (e.g. zinc sulphate heptahydrate), zinc sulfide, zinc sulphate hydrate (e.g. zinc sulfite dihydrate), Zinc telluride, zinc thiocyanate, zinc (II) salt of N-acetyl L-cysteine and mixtures thereof.
    Particularly preferred zinc salts include zinc citrate, zinc oxide, zinc chloride, zinc acetate, zinc stearate, zinc sulfate and mixtures thereof. Zinc citrate is particularly preferred.
    M. Moisturizers, Moisturizers and Skin Conditioning Agents
    The composition of the present invention may further comprise a moisturizer, moisturizer or other skin conditioning agent. Various such materials may be used, each of which may be present in an amount of about 0.1 to about 20%, more preferably about 1 to about 10%, most preferably about 2 to about 5%. These substances include guanidines; Glycolic acid and glycolate salts such as ammonium and quaternary alkyl ammonium; Lactic acid and lactate salts such as ammonium and quaternary alkyl ammonium; Any of a variety of forms of aloe vera (eg, aloe vera gel); Polyhydroxy alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; Polyethylene glycol; Sugars and starches; Sugar and starch derivatives such as alkoxylated glucose; Hyaluronic acid; Lactamide monoethanolamine; Acetamide monoethanolamine; And mixtures thereof.
    Also useful herein is the propoxylated glycerol described in US Pat. No. 4,976,953, which is incorporated herein by reference.
    Also useful are various C 1 -C 30 monoesters and polyesters of sugars and related materials. These esters are derived from sugar or polyol residues and one or more carboxylic acid residues. Depending on the acid and sugars comprised, these esters may be in liquid or solid form at room temperature. Examples of liquid esters are glucose tetraoleates and glucose tetraesters of soybean oil fatty acids (unsaturated), mannose tetraesters of mixed soybean oil fatty acids, galactose tetraesters of oleic acid, arabinose tetraesters of linoleic acid, xylose tetralinoleate , Galactose pentalate, sorbitol tetraoleate, sorbitol hexaester of unsaturated soybean oil fatty acid, xylitol pentalate, sucrose tetraoleate, sucrose pentalate, sucrose hexaoleate, sucrose hepatolalate , Sucrose octaoleate and mixtures thereof. Examples of solid esters include sorbitol hexaesters wherein the carboxylic acid ester residues are palmitate and arachidate in a 1: 2 molar ratio; Octaester of raffinose, wherein the carboxylic ester residue is 1: 3 molar ratio of linoleate and behenate; Heptaester of maltose wherein the esterified carboxylic acid residue is a 3: 4 molar ratio of sunflower seed oil fatty acid; Octaester of sucrose, wherein the esterified carboxylic acid residue is a 2: 6 molar ratio of oleate and behenate; And octaesters of sucrose, wherein the esterified carboxylic acid residues are laurate, linoleate and behenate in a 1: 3: 4 molar ratio. Preferred solid materials are sucrose polyesters having a degree of esterification of 7 to 8 and fatty acid residues in a molar ratio of C 18 mono- and / or di-unsaturated and behenic acid residues between 1: 7 and 3: 5. Particularly preferred solid sugar polyesters are octaesters of sucrose with about 7 behenic fatty acid residues and about 1 oleic acid residue in the molecule. Ester materials are also disclosed in US Pat. No. 2,831,854, US Patent No. 4,005,196, issued Jan. 25, 1977, and Jan. Pat. No. 4,005,195, issued January 25, 1977. US Patent No. 5,306,516 to Letton et al., April 26, 1994; US Patent No. 5,306,515 to Leton et al., April 26, 1994, issued April 26, 1994. US Patent No. 5,305,514 to Leton et al., US Patent No. 4,797,300 issued to Jandacek on January 10, 1989, US Patent No. 3,963,699 to Ricci et al., June 15, 1976, 1985 U.S. Patent No. 4,518,772, issued to Wolfenheim on May 21, and U.S. Patent No. 4,517,360, issued to Wolfenheim on May 21, 1985, all of which are incorporated herein by reference in their entirety. do.
    N. Other Optional Ingredients
    The compositions of the present invention may also include extracts obtained by suitable physical and / or chemical isolation from natural raw materials (eg, by-products of plants, fungi, microorganisms), including those known in topical body care products. Preferred extracts are those which enhance the skin appearance benefit of the present invention, preferably a safe effective amount, more preferably 0.1 to about 20%, even more preferably 0.5 to about 10%, most preferably 1 to about 5% It is used in the amount of. Such extracts include plant and fungal extracts, such as yeast extract, rice bran and plant Centella Asiatica. Natural extracts of Centella asiatica are preferred and are marketed under the trade names Centella asiatica EPCA (“Plant Extract of Centella asiatica”) and Genins amel from MMP, Plainfield, NJ. . Dohan's Amel is a more pure form of extract.
    Compounds known to stimulate collagen production can also be used in the present invention. Such compounds include Factor X (kinetine), Factor Z (zeatine), n-methyl taurine, dipalmitoyl hydroxyproline, palmitoyl hydroxy wheat protein, biopeptide CL (palmitoyl glycyl-histidyl- Lysine), ASC III (amplifier for collagen III synthesis, E. Merck, Germany), and beta glucan.
    The composition may also include natural ceramides, such as, for example, ceramides 1-6.
    The composition may also contain oil absorbents known in the art, such as clay (e.g. bentonite) and polymeric absorbents (e.g. MICROSPONGES 5647 and POLYTRAP), both of which are California, USA Commercially available from Advanced Polymer Systems, Inc. of Redwood City Microsponges 5647 is a polymer derived from styrene, methyl methacrylate and hydrogel acrylate / methacrylate. Mixture.
    Other examples of additional ingredients useful herein include water soluble vitamins and derivatives thereof such as vitamin C; Polyethylene glycol and polypropylene glycol; Polymers that aid in film formability and directivity of the composition (copolymers of eicosene and vinyl pyrrolidone, an example may be purchased as GAnex V-220 from GAF Chemical Corporation) It includes. In addition, cross-linked and non-crosslinked nonionic and cationic polyacrylamides such as Salcare SC92 with CTFA name Polyquaternum 32 (and) mineral oil, CTFA name Polyquaternum 37 (and) mineral oil Salcare SC95 with (and) PPG-1 Trideset-6, and Nonionic Sepi-Gel Polyacrylamide, available from Seppic Corp.). Useful are crosslinked and uncrosslinked carboxylic acid polymers and copolymers, such as those containing one or more monomers derived from acrylic acid, substituted acrylic acid, and salts and esters of acrylic acid and substituted acrylic acid, wherein the crosslinker is two or more Examples useful herein include polyhydric alcohols (e.g., useful herein are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerythritol and Carbopol in BFGoodrich). A carbomer commercially available as 900 series and a copolymer of C 10 -C 30 alkyl acrylate with at least one of acrylic acid, methacrylic acid or short chain (ie C 1 -C 4 alcohol) esters, wherein the crosslinking agent is an allyl ether of sucrose or pentaerythritol, these copolymers are acrylate / C 10 -C 30 alkyl acrylate ray Is known as a cross-linked polymer and non. F. is derived from hardened are commercially available in the Rich Company Carbopol 1342, page mulren (Pemulen) as TR-1 and page mulren TR-2). These carboxylic acid polymers and copolymers are described in U. S. Patent No. 5,087, 445 to Haffey et al., February 11, 1992, and U. S. Patent No. 4,509, 949, 1957 to Huang et al., April 5, 1985. US Patent No. 2,798,053, issued to Brown on July 2, 1989, which is incorporated herein by reference. CTFA International Cosmetic Ingredient Dictionary, 4th Ed, 1991, pp. 12 and 80, which is incorporated herein by reference.
    In addition, cosmetic ingredients such as perfume oils, pigments, colorants, essential oils, skin sensitizers, astringents, skin soothing agents, skin treatments and the like are useful herein, and non-limiting examples of these cosmetic ingredients are cloves, menthol, camphor, eucalyptus oil, oil Genols, menthyl lactate, hamamelis distillate, bisabolol, dipotassium glycyrginate and the like.
    Method of Preparation of the Composition
    The composition of the present invention is generally prepared by conventional methods as known in the art of preparing topical compositions. Such methods typically involve mixing the components in a relatively uniform state in one or more steps, with or without heating, cooling, vacuuming, and the like.
    How to control your skin condition
    The compositions of the present invention may be used in combination with visible and / or tactile discontinuities of the skin, signs of skin aging and visible and / or discontinuities in the skin associated with skin aging (fine lines, wrinkles, large pores, surface roughness and other skin aging). Useful for regulating skin conditions (especially human skin, more particularly human facial skin) of mammals, including related tissue discontinuities. Such control includes prophylactic and therapeutic control.
    Modulation of the skin condition includes topical application of the compositions of the invention to the skin in a safe effective amount. The amount of application, frequency of application and duration of application is highly dependent on the amount of vitamin B 3 compound and / or other ingredients in a given composition, the degree of control desired (ie, in terms of skin aging present in the user and subsequent rate of skin aging). Varies.
    In a preferred embodiment, the composition is applied to the skin for a long time. "Long term topical application" is a long term, preferably at least about 1 week, more preferably at least about 1 month, even more preferably at least about 3 months, even more preferably at least about 6 months, over the lifetime of the user, Most preferably, it is intended to continuously apply the composition over about one year or more. It may be effective after various maximum periods of use (eg 5, 10 or 20 years), but long term application is desirable for the lifetime of the user. Typically, the application is at least about once per day over a long period of time, but the application interval may vary from about once a week to at least about three times a day.
    A wide range of compositions of the present invention can be used to provide skin appearance and / or tactile benefits. The amount of composition typically applied per application is from about 0.1 to about 10 mg per cm 2 of skin. Particularly useful dosages are about 2 mg / cm 2.
    Control of the skin condition is preferably carried out by applying a composition in the form of skin lotions, creams, cosmetics, etc. ("residual composition") remaining on the skin to provide some cosmetic, prophylactic, therapeutic or other benefit. . After the composition has been applied to the skin, it remains on the skin for at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, most preferably at least several hours, for example at most about 12 hours. It is preferable to make it.
    The following examples further disclose and demonstrate aspects within the scope of the invention. The present examples are given solely for the purpose of illustrating the invention and are not intended to limit the invention, and many modifications may be made without departing from the spirit and scope of the invention.
    Example 1
    Skin creams are prepared by conventional methods from the following ingredients.
    Ingredient (CTFA Name)weight% A phaseWater U.S.P.57.31Disodium EDTA0.13Methyl paraben0.25glycerin3.00Zinc citrate1.00 B phaseCetyl alcohol0.56Stearyl alcohol2.03Behenyl alcohol0.22Stearette-21 (breeze 721)0.37Stearette-2 (breeze 72)1.10Distearyldimonium chloride (Varisoft TA-100)0.95Profile paraben0.10Polypropylene Glycol-15 Stearyl Ether (Arlamol E)3.25 C phasePolypropylene Glycol-15 Stearyl Ether (Alamole E)2.17Titanium dioxide0.75 D phaseNiacinamide5.00Citric acid0.19Water U.S.P.17.0050% NaOH0.94 E phaseBenzyl alcohol0.50Silicone fluids (DC Q2-1401; cyclomethicone / dimethiconol-50 / 50 blends0.75Dimethicone 10cst1.00Polyethylene Low Density Beads1.00 F phaseenjoyment0.10 G phase50% NaOH0.33
    Phase A components are blended using a suitable mixer (eg Tekmar Model RW20DZM) and heated under stirring to a temperature of 70-80 ° C. Separately, the B phase components are blended with a suitable mixer and heated with mixing to melt the components. Separately, the phase C ingredients are blended and ground to obtain an acceptable smooth mixture (eg using a Tekmar T50 mill).
    The C phase mixture is added to the B phase mixture and mixed. The resulting mixture is then added to the mixture of phase A under mixing, cooled in a cold water bath, triturated and stirred continuously. When the temperature rises to 40 ° C. the combination is removed from the bath and stirring is continued.
    Separately, the D phase components are blended under stirring until dissolved and then added to the combination of A-C materials.
    Separately, the phase E ingredients are blended by mixing until smooth and continuous and added to the combination of A-D materials. Perfume oil is added and mixed, followed by NaOH. If necessary, adjust the pH to 5.5.
    The composition is applied at an amount of 2 mg per cm 2 to the wrinkled, aged or photodamaged facial skin once or twice a day for at least 3 to 6 months to reduce fine lines and wrinkles and improve skin surface tissue. .
    Example 2
    The above components are used to prepare an emulsion in a conventional manner.
    ingredientweight% Silicone Fluid (Dow Corning DC 345)15.0 Silicone Fluid (Dow Corning DC 3225C)2.5 Silicone Fluid (Gold Schmidt Avill We09)2.5 water71.4 Niacinamide5.0 Tetrasodium EDTA0.1 Benzyl alcohol0.3 Methyl paraben0.2 glycerin3.0
    Glycerin and then niacinamide are added to the water under stirring in a suitable vessel to introduce water to form an aqueous phase. Methyl paraben dissolved in benzyl alcohol is added to the mixture under stirring. EDTA is added to this mixture under stirring.
    The silicone fluid is added under stirring to form the silicone phase in a separate suitable vessel.
    Under stirring, the aqueous phase is slowly added to the silicone to form an emulsion.
    The composition is applied at an amount of 2 mg per cm 2 to the wrinkled, aged or photodamaged facial skin once or twice a day for at least 3 to 6 months to reduce fine lines and wrinkles and improve skin surface tissue. .
    Example 3
    Skin creams are prepared by conventional methods from the following ingredients.
    Ingredient (CTFA Name)weight% A phaseWater U.S.P.63.96Disodium EDTA0.15glycerin5 B phaseCetyl hydroxyethyl cellulose0.15Methyl paraben0.25 C phaseCetyl alcohol0.5Stearyl alcohol0.5Behenyl alcohol0.5Cetyl ricinolate3Stearette-2 (breeze 72)1.05Distearyldimonium chloride (varisoft TA-100)0.25Profile paraben0.10Myristeel Myristate1.5Capryl / Capritriglyceride1.5Mineral oil2Fatty acid esters of sugars * OnePolypropylene Glycol-15 Stearyl Ether (Alamole E)1.05 D phaseDimethicone 10cst (Dow Corning)2 E phaseNiacinamide5Water U.S.P.10 F phaseBenzyl alcohol0.5 G phase50% NaOH0.04 * C 1 -C 30 monoesters or polyesters of sugars and one or more carboxylic acid residues as described herein, preferably having a degree of esterification of 7 to 8 and fatty acid residues having a C 18 mono- and / or diunsaturated residue. Sucrose polyesters with a molar ratio of henic acid residues between 1: 7 and 3: 5, preferably octaesters of sucrose with about 7 behenic fatty acid residues and about 1 oleic acid residue in the molecule, for example cottonseed oil Sucrose esters of fatty acids.
    Phase A components are blended using a suitable mixer (eg Techmar Model RW20DZM) and heated under stirring to a temperature of about 70-80 ° C. Cetyl hydroxy ethyl cellulose and methyl paraben are added under mixing at a temperature of about 70-80 ° C. to melt the components. Separately, the phase C ingredients are blended and ground to obtain an acceptable smooth mixture (eg using a Tekmar T50 mill).
    Phase C mixture is added to the mixture and mixed. When the temperature rises to about 45 ° C. remove the combination from the bath and continue stirring. Add dimethicone and mix.
    Separately, the phase E ingredients are blended by mixing until smooth and continuous and added to the mixture. Add to benzyl alcoholol and mix, then add NaOH. If necessary, adjust the pH to 7.
    The composition is applied at an amount of 2 mg per cm 2 to the wrinkled, aged or photodamaged facial skin once or twice a day for at least 3 to 6 months to reduce fine lines and wrinkles and improve skin surface tissue. .
    Example 4
    Skin creams are prepared by conventional methods from the following ingredients.
    ingredientweight% A phaseBenzyl alcohol0.30Methyl p-hydroxybenzoate (a.k.a.methyl paraben)0.20ethanol3.00 B phasewater60.60-61.35Disodium EDTA0.50Glycerol10.00Hexylene glycol2.00Niacinamide2.00Triethanol amine0.05Butylated hydroxytoluene0.10 C phaseDow Corning 345 Fluid12.50Avill WE-092.50Dow Corning-3225C2.50vaseline1.50Retinol (10% in soybean oil)0.75-1.50Fatty acid esters of sugars * 1.00 * See Example 3
    Phase A components are blended using a suitable mixer (eg, Techmar Model RW20DZM). The phase B components are blended on phase A using a suitable mixer. Separately, the C phase components are blended until uniform. The C phase mixture is added to the A / B phase mixture, mixed until homogeneous and emulsified and milled to obtain an acceptable smooth mixture (eg using a Tekmar T50 mill).
    The composition is applied at an amount of 2 mg per cm 2 to the wrinkled, aged or photodamaged facial skin once or twice a day for at least 3 to 6 months to reduce fine lines and wrinkles and improve skin surface tissue. .
    Retinol is added with water in an amount of from 0.025 (0.25% of 10% retinol in soybean oil) to 100% and the amount of other ingredients can be prepared in the same manner as other skin creams with reduced retinol content as shown.
    While specific aspects of the invention have been described, those skilled in the art will recognize that various changes and modifications of the invention can be made without departing from the spirit and scope of the invention. It is intended that the appended claims cover all such modifications as fall within the scope of the invention.
    权利要求:
    Claims (10)
    [1" claim-type="Currently amended] (a) a safe and effective amount of an active ingredient, essentially consisting of a vitamin B 3 compound, for controlling visible and / or tactile discontinuities in skin tissue of a mammal; And (b) applying a composition comprising a carrier for the active ingredient in a safe effective amount to the skin of the mammal,
    A method of controlling visible and / or tactile discontinuity in skin tissue of a mammal.
    [2" claim-type="Currently amended] (a) a safe effective amount of a vitamin B 3 compound; And (b) applying a composition comprising a carrier for a vitamin B 3 compound to a mammalian skin in a safe effective amount,
    A method of controlling skin pore size in a mammal.
    [3" claim-type="Currently amended] (a) a safe effective amount of a vitamin B 3 compound of from 2 to 5%;
    (b) a safe effective amount of retinoids; And
    (c) carriers for vitamin B 3 compounds and retinoids
    Characterized in that the composition comprising a safe effective amount applied to the skin of the mammal,
    A method of controlling skin conditions, preferably visible and / or tactile discontinuities of skin tissue, more preferably wrinkles, lines and / or skin pores.
    [4" claim-type="Currently amended] The method according to any one of claims 1 to 3,
    The vitamin B 3 compound is selected from niacinamide, derivatives of niacinamide, non-vascular expandable esters of nicotinic acid and mixtures thereof, preferably selected from niacinamide, tocopherol nicotinate and mixtures thereof, more preferably The method is niacinamide.
    [5" claim-type="Currently amended] The method according to any one of claims 1 to 4,
    The vitamin B 3 compound is substantially free of salts of the vitamin B 3 compound and / or is substantially uncomplexed.
    [6" claim-type="Currently amended] The method according to any one of claims 1 to 5,
    And the carrier comprises a hydrophilic diluent.
    [7" claim-type="Currently amended] The method according to any one of claims 1 to 6,
    The composition,
    (a) hydroxy acids, preferably salicylic acid;
    (b) a dermabrasion agent, preferably selected from zwitterionic surfactants;
    (c) sunscreens preferably selected from the group consisting of zinc oxide, titanium dioxide, parsol 1789, parsol MCX, phenyl benzimidazole sulfonic acid, octocrylene and mixtures thereof;
    (d) antioxidants preferably selected from esters of tocopherols; And
    And a compound selected from the group consisting of mixtures thereof.
    [8" claim-type="Currently amended] The method of claim 2,
    The composition is preferably selected from the group consisting of retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal, and mixtures thereof, more preferably retinol, retinyl palmitate and their Further comprising a retinoid selected from the group consisting of mixtures.
    [9" claim-type="Currently amended] (a) a safe effective amount of up to 2 to 5%, preferably selected from the group consisting of niacinamide, niacinamide derivatives, non-vascular expandable esters of nicotinic acid and mixtures thereof, more preferably niacinamide, tocopherol nico Tinate and mixtures thereof, most preferably niacinamide; Preferably a vitamin B 3 compound that is not substantially contained in salt form and / or is substantially uncomplexed;
    (b) is preferably selected from the group consisting of retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and mixtures thereof, more preferably retinol, retinyl palmitate and their A safe effective amount of retinoids selected from the group consisting of mixtures, preferably 0.01 to 2%; And
    (c) carriers for vitamin B 3 compounds and retinoids, preferably containing a hydrophilic diluent
    A topical composition suitable for controlling skin conditions, comprising: a.
    [10" claim-type="Currently amended] The method of claim 9,
    (a) hydroxy acids, preferably salicylic acid;
    (b) a dermabrasion agent, preferably selected from zwitterionic surfactants;
    (c) sunscreens preferably selected from the group consisting of zinc oxide, titanium dioxide, parsol 1789, parsol MCX, phenyl benzimidazole sulfonic acid, octocrylene and mixtures thereof;
    (d) antioxidants preferably selected from esters of tocopherols; And
    A composition further comprising a compound selected from the group consisting of mixtures thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP4990268B2|2012-08-01|Personal care compositions containing dipeptides
    US5980921A|1999-11-09|Topical compositions for regulating the oily/shiny appearance of skin
    EP1032352B2|2009-05-13|Skin care compositions and method of improving skin appearance
    ES2211512T3|2004-07-16|Cosmetic compositions containing vitamin b3.
    EP2099418B1|2017-06-14|Skin care composition
    AU2002325856B2|2005-01-06|Agent containing fat |, which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue
    CA2212850C|2005-11-08|Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids
    US6051602A|2000-04-18|Methods for regulating skin appearance
    US8063097B2|2011-11-22|Compositions and methods for regulating mammalian keratinous tissue
    EP0514067B2|2004-07-14|Cosmetic composition
    KR100385781B1|2003-06-02|Skin care kit
    JP4152987B2|2008-09-17|Regulation of mammalian hair growth
    US5855893A|1999-01-05|Trichodesma lanicum seed extract as an anti-irritant in compositions containing hydroxy acids or retinoids
    AU725960B2|2000-10-26|Cosmetic composition with long chain unsaturated retinol fatty acid esters
    ES2200340T3|2004-03-01|Compositions for skin care and method to improve the skin aspect.
    EP1156772B1|2002-11-20|Skin care compositions
    US20030147830A1|2003-08-07|Topical skin and/or hair compositions containing protein
    US8530426B2|2013-09-10|Cosmetic or dermopharmaceutical composition comprising at least one UDP glucuronosyl transferase | enzymes inducer
    CN100421644C|2008-10-01|Regulation of mammalian keratinous tissue using hexamidine compositions
    US20020044913A1|2002-04-18|Cosmetics to support skin metabolism
    ES2381359T3|2012-05-25|Compositions containing mixtures of tetrapeptides and tripeptides
    CN1993102B|2010-12-08|Compositions comprising an amidine and an alkane polyol
    ES2192770T5|2009-06-10|Compositions for skin care and method for improving skin appearance.
    US20050053563A1|2005-03-10|Stable compositions containing ethanolamine derivatives and glucosides
    US20050214332A1|2005-09-29|Skin care composition containing dehydroacetic acid and skin care actives
    同族专利:
    公开号 | 公开日
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1996-10-21|Priority to US60/025,242
    1996-10-21|Priority to US60/028,902
    1996-10-21|Priority to US60/016,043
    1997-04-23|Application filed by 데이비드 엠 모이어, 더 프록터 앤드 갬블 캄파니
    1997-04-23|Priority to KR1019980708523A
    1997-04-23|Priority claimed from KR1019980708523A
    2000-02-25|Publication of KR20000010622A
    2002-12-18|Application granted
    2002-12-18|Publication of KR100357848B1
    优先权:
    申请号 | 申请日 | 专利标题
    US60/025,242|1996-10-21|
    US60/028,902|1996-10-21|
    US60/016,043|1996-10-21|
    KR1019980708523A|KR100357848B1|1996-04-23|1997-04-23|Methods of regulating skin appearance with vitamin b3 compound|
    [返回顶部]